Menopause is the permanent cessation of menstruation due to loss of ovarian follicular activity, while the climacteric is the transitional period marked by vasomotor, psychological, and urogenital symptoms resulting from declining estrogen levels.

Exam domain	One-glance essentials
Definition / diagnosis	*Menopause is diagnosed retrospectively after 12 months of amenorrhoea from loss of ovarian follicular activity* ^[1]^[2]^[3] The climacteric or perimenopause spans the symptomatic transition before and after the final menstrual period ^[1]
Epidemiology / risks	Natural menopause usually occurs around age 50–51; smoking, ovarian surgery, chemotherapy, and genetic or autoimmune disease can bring it earlier ^[1]^[2] Premature ovarian insufficiency is loss of ovarian function before 40 and needs distinct evaluation ^[2]
Core mechanism	Follicle depletion → falling inhibin and oestradiol → rising FSH and unstable thermoregulation → vasomotor symptoms ^[1] Oestrogen loss accelerates bone resorption and causes vulvovaginal and lower urinary tract atrophy ^[1]^[2]
Clinical picture	*Hot flushes and night sweats are characteristic*; sleep disturbance, mood change, sexual dysfunction, vaginal dryness, and urinary symptoms are common ^[1] Any postmenopausal bleeding requires investigation rather than attribution to menopause ^[1]^[2]
Investigations	In an otherwise healthy person aged 45 or older with typical symptoms, diagnosis is usually clinical; routine FSH testing is unnecessary ^[1]^[3] Investigate atypical symptoms, early menopause, pregnancy possibility, thyroid disease, anaemia, or postmenopausal bleeding as indicated ^[2]
Management	*Menopausal hormone therapy is the most effective treatment for vasomotor symptoms*; add a progestogen if the uterus is present ^[1]^[2]^[3] Use local vaginal oestrogen for genitourinary syndrome; offer non-hormonal options when hormones are contraindicated or declined ^[1]^[3]
Complications	Long-term consequences include osteoporosis and fractures, genitourinary syndrome, and adverse cardiometabolic change ^[1]^[2] Systemic hormone therapy can increase VTE or breast-cancer risk depending on route, regimen, duration, and baseline risk ^[1]
Prevention / follow-up	Use lifestyle measures, smoking cessation, exercise, calcium and vitamin-D adequacy, and age-appropriate cardiovascular and bone-risk assessment ^[1]^[2] Review hormone therapy periodically and investigate unscheduled bleeding according to regimen and timing ^[1]
Exam traps	*Do not use FSH to confirm typical menopause in most people aged 45 or older* ^[1]^[3] Hormone therapy is for symptoms and bone protection in selected patients, not for primary prevention of cardiovascular disease or dementia ^[1]^[2]^[3]

References

^[1] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (pp. 38–41 — menopause assessment and treatment) ^[2] Senior notes: Adrian Lui Gynecology Notes.pdf (pp. 32–38 — menopause and complications) ^[3] NICE guideline NG23: Menopause: identification and management (updated April 2026)

Climacteric Symptoms and Menopause

Let's start with the language — getting terminology right is essential because examiners love to test whether you can distinguish these closely related but distinct terms.

Climacteric: the years of waning ovarian function which marks the transition from the reproductive to the non-reproductive state ^[1]. Think of it like "the menopause era" — it's a gradual process, not a single event. The word comes from the Greek klimakter (κλιμακτήρ) = "rung of a ladder" or "critical period," reflecting the idea of a physiological step-change.

Menopause: the permanent cessation of ovarian function and fertility — a specific event (the final menstrual period) — diagnosed retrospectively after cessation of menses for 12 months in a previously cycling woman ^[1]^[2]. This is crucial: menopause is a point in time, not a period. You can only say "that was menopause" after 12 months of amenorrhoea have elapsed. The word: "meno-" (Greek mēn = month/menstruation) + "pause" (Greek pausis = cessation).

Perimenopause: the period beginning with the first clinical, biological and endocrinological features of the approaching menopause, and ending 12 months after the final menstrual period ^[1]. This is the window where women are most symptomatic — cycles become irregular, hormone levels fluctuate wildly, and vasomotor symptoms peak.

Premature menopause (Premature Ovarian Insufficiency, POI): menopause occurring before age 40. This is pathological and warrants investigation — it is NOT a normal variant.

Early menopause: menopause occurring between ages 40–45.

Postmenopause: the period commencing 12 months after the final menstrual period and lasting the rest of life.

Key Distinction for Exams

Menopause = a single retrospective event (the last period). Climacteric = the entire transitional era (years). Perimenopause = the symptomatic transition window. Don't confuse these — they are tested separately.

2. Epidemiology

Average age of natural menopause: ~51 years (range 45–55) worldwide.
In Hong Kong: the average age is approximately 51 years, consistent with global data ^[3].
The perimenopause typically begins in the mid-to-late 40s (average onset ~47 years) and lasts approximately 4–8 years.

Up to 75–80% of perimenopausal women experience vasomotor symptoms (hot flushes).
Of those, approximately 25% find them severe enough to seek medical attention.
Vasomotor symptoms last a median of 7.4 years (the SWAN study); in women who start having flushes in early perimenopause, symptoms may persist for > 10 years.
There is ethnic variation: East Asian women (including Hong Kong Chinese) tend to report fewer and less severe vasomotor symptoms compared to Caucasian women, though they may report more musculoskeletal and psychological symptoms. This may relate to higher phytoestrogen (soy isoflavone) intake in Asian diets, as well as cultural differences in symptom reporting.

Hong Kong has a rapidly ageing population: the proportion of women over 50 is increasing, making climacteric health a growing public health concern.
Osteoporosis prevalence in HK women: 60–69y: 1:6; 70–79y: 1:5; ≥80y: 1:4 ^[4] — driven substantially by postmenopausal oestrogen deficiency.
Cardiovascular disease becomes the leading cause of mortality in postmenopausal HK women.

Understanding what accelerates ovarian ageing or depletes follicular reserve:

Risk Factor	Mechanism
Smoking	Polycyclic aromatic hydrocarbons are directly toxic to ovarian follicles → accelerates follicular atresia. Shifts menopause 1–2 years earlier.
Family history	Genetic factors account for ~50% of variation in menopausal age (e.g., genes regulating DNA repair, follicular growth).
Nulliparity	Ovulation without "rest" from pregnancy/lactation → more cumulative follicular depletion (though this effect is modest).
Prior ovarian surgery	Direct removal/destruction of ovarian tissue → reduced follicular pool (e.g., cystectomy for endometrioma).
Chemotherapy/radiotherapy	Alkylating agents (cyclophosphamide) are directly gonadotoxic → dose-dependent follicular destruction. Pelvic RT causes similar damage.
Autoimmune oophoritis	Autoimmune destruction of ovarian follicles; associated with other autoimmune conditions (Addison's, hypothyroidism).
Chromosomal abnormalities	e.g., Turner syndrome (45,X), Fragile X premutations → accelerated follicular loss.
Low BMI/eating disorders	Functional hypothalamic suppression; while this causes amenorrhoea rather than true menopause, prolonged hypo-oestrogenism mimics menopausal effects.
Ethnicity	Hispanic and African-American women tend to reach menopause slightly earlier; Asian women slightly later on average.

4. Anatomy and Physiology — The Hypothalamic-Pituitary-Ovarian (HPO) Axis

To understand menopause, you must understand what stops working.

Hypothalamus → pulsatile release of GnRH (gonadotropin-releasing hormone) into the hypophyseal portal system.
Anterior pituitary → in response, gonadotrophs secrete FSH (follicle-stimulating hormone) and LH (luteinising hormone).
Ovary → FSH recruits a cohort of antral follicles each cycle. The dominant follicle produces oestradiol (E2) from granulosa cells (via aromatisation of androgens produced by theca cells under LH stimulation).
Negative feedback: rising E2 → suppresses FSH and LH (keeps other follicles from growing).
Positive feedback: at a critical E2 threshold sustained for ~36 hours → triggers the LH surge → ovulation.
Corpus luteum forms post-ovulation → produces progesterone (+ oestradiol) → prepares endometrium for implantation.
If no implantation → corpus luteum regresses → progesterone and oestradiol drop → endometrial shedding (menstruation) → loss of negative feedback → FSH rises → next cycle begins.

Hormone	Source	Key Actions
Oestradiol (E2)	Granulosa cells of dominant follicle; corpus luteum	Endometrial proliferation, breast duct development, vaginal/urethral mucosal maintenance, bone formation (↓RANKL, ↑OPG), cardioprotective lipid profile (↑HDL, ↓LDL), CNS thermoregulation, skin collagen maintenance
Progesterone	Corpus luteum; placenta	Endometrial secretory transformation, thermogenic (↑basal body temp), anti-oestrogenic effect on endometrium (prevents hyperplasia)
Inhibin B	Granulosa cells (early follicular phase)	Selective FSH suppression (fine-tunes follicle recruitment)
Anti-Müllerian Hormone (AMH)	Pre-antral and small antral follicles	Marker of ovarian reserve; modulates follicle recruitment
Androgens (testosterone, androstenedione)	Theca cells; adrenals	Libido, body hair, aromatised to oestrogens peripherally

At birth: ~1–2 million primordial follicles.
At puberty: ~300,000–400,000.
Over reproductive life: ~400 are ovulated; the vast majority undergo atresia (apoptotic follicular death).
The rate of atresia accelerates after age ~37.5 (when follicle count drops below ~25,000) — this is when fertility declines sharply.
By menopause: essentially no functional follicles remain (< 1,000).

5. Etiology and Pathophysiology of Menopause

Menopause is fundamentally about follicular depletion. The ovary simply runs out of responsive follicles. Here's the cascade:

Let's break this down step by step:

Declining follicular pool → fewer granulosa cells → ↓ inhibin B and ↓ oestradiol production.
↓ Inhibin B → loss of selective negative feedback on FSH → ↑ FSH (this is the earliest hormonal change, occurring years before menopause while cycles may still be regular).
↑ FSH attempts to "rescue" the ovary by recruiting more follicles, but paradoxically this accelerates depletion — a vicious cycle.
Initially, ↑ FSH may even cause higher-than-normal oestradiol levels in some cycles (hyper-stimulation of remaining follicles) → this explains the erratic, sometimes heavy periods in perimenopause.
Eventually, so few follicles remain that even high FSH cannot sustain follicular development → oestradiol levels fall permanently.
No ovulation → no corpus luteum → no progesterone → anovulatory cycles with erratic bleeding → eventually amenorrhoea.
Loss of negative feedback on hypothalamus/pituitary → persistently elevated FSH and LH (hypergonadotropic hypogonadism).

The Endocrine Profile of Menopause

Post-menopausal hormonal picture:

↑↑ FSH (> 30–40 IU/L — most reliable marker)
↑ LH (but less dramatically than FSH)
↓↓ Oestradiol (< 70–110 pmol/L)
↓ Inhibin B (unmeasurably low)
↓ AMH (undetectable)
↓ Progesterone (no corpus luteum)

Note: Postmenopausal women still produce some oestrogen — but it is oestrone (E1), not oestradiol. Oestrone is produced by peripheral aromatisation of adrenal androgens (androstenedione) in adipose tissue. This is why obese postmenopausal women have higher oestrogen levels (and higher risk of endometrial hyperplasia/cancer but potentially fewer vasomotor symptoms).

Type	Cause	Notes
Natural menopause	Age-related follicular depletion	Average age 51; diagnosis is clinical and retrospective
Premature Ovarian Insufficiency (POI)	Menopause < age 40	Causes: idiopathic (most), genetic (Turner, Fragile X), autoimmune (anti-ovarian Ab), iatrogenic (chemo, RT, surgery), infections (mumps oophoritis)
Surgical menopause	Bilateral oophorectomy (± hysterectomy)	Abrupt onset; symptoms often more severe because of sudden oestrogen withdrawal (no gradual adaptation)
Iatrogenic menopause	Chemotherapy, pelvic radiotherapy	May be temporary or permanent depending on age and dose
Medical/chemical menopause	GnRH agonists (e.g., leuprolide for endometriosis, fibroids)	Reversible upon cessation

Pathophysiology of Specific Climacteric Symptoms

Now let's connect each symptom group to the underlying hormonal changes — this is how you should think about it on ward rounds.

Vasomotor symptoms: hot flushes, sweating, palpitation, dizziness ^[1]^[2]

Pathophysiology:

The thermoregulatory centre is in the hypothalamic preoptic area.
Normally, there is a "thermoneutral zone" — a range of core body temperatures within which neither sweating nor shivering is triggered.
Oestrogen modulates this thermoneutral zone (via effects on neurotransmitters: noradrenaline, serotonin, and neurokinin B/kisspeptin pathways).
In oestrogen deficiency, the thermoneutral zone narrows dramatically.
Even tiny elevations in core temperature (< 0.5°C) now trigger a full heat dissipation response: peripheral vasodilation (the "flush" — sudden warmth and redness in face, neck, chest), sweating, and tachycardia/palpitation.
This is followed by a reflex drop in core temperature → chills.

Why dizziness? Sudden peripheral vasodilation → transient drop in blood pressure → orthostatic-type dizziness.

Why palpitations? Sympathetic activation as part of the thermoregulatory response → tachycardia.

Key neuroscience update (2024–2026): The KNDy neuron system (kisspeptin/neurokinin B/dynorphin) in the hypothalamic arcuate nucleus is now recognised as a central driver of vasomotor symptoms. Oestrogen normally inhibits NKB release. Without oestrogen → ↑NKB → triggers thermoregulatory dysfunction. This is the basis for the neurokinin-3 (NK3) receptor antagonist fezolinetant — the first non-hormonal drug specifically approved for vasomotor symptoms (FDA 2023).

Psychological symptoms: loss of energy and drive, loss of concentration, irritability, anxiety, depression, mood fluctuations, sleep disturbances ^[1]^[2]

Can be multifactorial: Bio-psycho-social factors! ^[1]^[2]

Pathophysiology — the "Bio" component:

Oestrogen modulates serotonergic, dopaminergic, and noradrenergic neurotransmission.
Oestrogen enhances serotonin synthesis (↑ tryptophan hydroxylase), decreases serotonin reuptake, and upregulates 5-HT₂A receptors → net effect is enhanced serotonergic tone.
Oestrogen withdrawal → ↓ serotonin → depressed mood, anxiety, irritability.
Oestrogen also has neuroprotective and neurotrophic effects (via BDNF) → withdrawal impairs cognition and concentration.
Fluctuation in oestrogen (as opposed to stable low levels) is particularly destabilising to mood — this is why perimenopause is worse than postmenopause for mood symptoms.
Sleep disturbances are partly secondary to nocturnal hot flushes (night sweats cause repeated awakenings) and partly due to direct effects of oestrogen/progesterone withdrawal on sleep architecture (oestrogen promotes REM sleep; progesterone has sedative/GABAergic properties).

The "Psycho-Social" component:

Life stage: children leaving home ("empty nest"), ageing parents, career changes.
Body image: changes in weight, skin, hair.
Relationship changes.
Cultural attitudes toward ageing and menopause.

Exam Pearl

When a perimenopausal woman presents with depression, always consider both the hormonal contribution and psychosocial factors. The lecture slides emphasise this is multifactorial: bio-psycho-social factors. Don't reduce it to "just hormones."

Sexual dysfunction: dyspareunia — atrophic change; decreased libido. Can be multifactorial. ^[1]^[2]

Pathophysiology:

Dyspareunia (painful intercourse):
- Oestrogen maintains the vaginal epithelium — it keeps it thick (stratified squamous, well-glycogenated), well-vascularised, elastic, and lubricated.
- Oestrogen deficiency → vaginal atrophy: the epithelium thins, loses rugae, becomes pale/dry, and the pH rises (from acidic ~3.5–4.5 to > 5.0 because Lactobacillus species decrease as glycogen decreases).
- Thin, dry, inelastic vaginal mucosa → friction and micro-trauma during intercourse → pain.
- Reduced blood flow → ↓ transudate lubrication.
Decreased libido:
- Multifactorial: reduced ovarian testosterone production (ovary contributes ~25% of circulating testosterone; the rest is adrenal); dyspareunia itself causes avoidance; psychological factors (mood, body image, relationship quality); fatigue from sleep disturbance.
- Note: after menopause, the ovarian stroma can still produce some androgens under LH stimulation, so testosterone does not drop as dramatically as oestradiol.

Urogenital atrophy ^[1]:

Vaginal	Urinary
Dryness	Urgency
Burning	Frequency
Pruritus	Dysuria
Dyspareunia	Urinary tract infection
Prolapse	Incontinence
	Voiding difficulties

Pathophysiology: The vagina, urethra, bladder trigone, and pelvic floor all share an embryological origin from the urogenital sinus and are richly populated with oestrogen receptors (ERα and ERβ).

Vaginal symptoms (dryness, burning, pruritus, dyspareunia):
- Oestrogen withdrawal → thinning of vaginal epithelium → loss of glycogen → ↓ Lactobacillus → ↑ pH → vulnerability to non-Lactobacillus organisms → chronic inflammation and irritation.
- Loss of collagen and elastic fibres in the vaginal wall → loss of elasticity.
- Reduced vascularity → ↓ transudate → dryness.
Urinary symptoms (urgency, frequency, dysuria, recurrent UTI, incontinence):
- Urethral and bladder trigone atrophy → ↓ urethral closure pressure → stress incontinence.
- Altered urethral and bladder epithelium → ↑ susceptibility to bacterial adhesion → recurrent UTIs.
- Urgency and frequency: thinned urothelium + changes in detrusor muscle → overactive bladder symptoms.
- Dysuria: may mimic UTI even without infection (atrophic urethritis).
Prolapse : loss of collagen and pelvic floor tone due to oestrogen deficiency + prior childbirth → uterovaginal prolapse (cystocele, rectocele, uterine descent).

GSM vs Vasomotor Symptoms

A common mistake: unlike vasomotor symptoms which often improve over years, urogenital atrophy is progressive and does NOT improve without treatment. It gets worse with time. This is important for counselling patients.

Cardiovascular disease: incidence increases after menopause. Oestrogen is probably protective to the vasculature and has a favourable effect on lipid profile. ^[1]

Pathophysiology of postmenopausal cardiovascular risk:

Lipid profile: Oestrogen → ↑ HDL (by ↑ hepatic apoA-I synthesis and ↓ hepatic lipase activity), ↓ LDL (by ↑ hepatic LDL receptor expression), ↓ Lp(a). Oestrogen withdrawal reverses all of this → atherogenic profile.
Vascular endothelium: Oestrogen → ↑ NO (via eNOS upregulation) → vasodilation and anti-atherosclerotic effect. Withdrawal → endothelial dysfunction.
Insulin sensitivity: Oestrogen improves insulin sensitivity. Menopause → ↑ insulin resistance → metabolic syndrome.
Coagulation: Complex effects — oestrogen is both pro-coagulant (↑ factors VII, X, fibrinogen) and anti-coagulant (↑ protein C, ↑ fibrinolysis). Net effect of withdrawal is debatable but overall cardiovascular risk rises.
Central fat deposition: Oestrogen favours gluteofemoral (subcutaneous) fat distribution. Menopause → shift to central (visceral) adiposity → ↑ cardiometabolic risk.
Blood pressure: modest rise in BP postmenopause.

Result: Cardiovascular disease (ischaemic heart disease, stroke) becomes the leading cause of death in postmenopausal women — surpassing breast cancer.

Postmenopausal osteoporosis: oestrogen deficiency leads to bone loss. Postmenopausal osteoporosis is an important risk factor for fracture. ^[1]

Pathophysiology (detailed — linking to Ryan Ho Endocrine notes ^[4]):

Oestrogen is the key regulator of bone remodelling:

Oestrogen acts to ↑ bone formation and ↓ bone resorption by: ^[4]
- ↓ osteoblast apoptosis by ↓ TGF-β secretion ^[4]
- ↓ osteoblast-induced osteoclastogenesis by ↓ cytokine secretion and ↓ RANKL expression ^[4]
- ↑ osteoclast apoptosis by ↑ TNF-α secretion ^[4]

In oestrogen deficiency (the RANKL/OPG system):

RANKL expressed by osteoblasts stimulates osteoclast differentiation by binding to RANK on osteoclast precursors ^[4]
Osteoprotegerin (OPG) secreted by osteoblasts acts as a competitive inhibitor of RANK-RANKL interaction ^[4]
17β-estradiol → ↓ RANKL and ↓ OPG → net effect favours bone formation ^[4]
Oestrogen withdrawal → ↑ RANKL:OPG ratio → ↑ osteoclast differentiation, number, and survival → net bone resorption >> formation
↑ number of remodelling units ^[4] → more sites of active resorption
Trabecular bone (20% of mass but 80% of turnover) is disproportionately affected → vertebral fractures predominate early

Timeline:

Type 1 (postmenopausal) osteoporosis: occurs ≤ 15–20y post-menopause, hormonal-related ^[4]
Type 2 (age-related) osteoporosis: occurs in M+F > 75y, ageing-related ^[4]
Bone loss is most rapid in the first 5–7 years postmenopause (up to 3–5% per year of trabecular bone loss), then slows to ~1%/year.

Clinical consequence:

Fragility fractures: vertebral collapse, hip fracture, distal forearm fracture ^[4]^[5]
Vertebral collapse: acute mechanical LBP ± radiation with height loss and kyphosis ^[4]
DEXA screening recommended for postmenopausal women with risk factors; T-score ≤ –2.5 = osteoporosis ^[5]

System	Effect	Mechanism
Skin	Thinning, dryness, wrinkling, bruising	Oestrogen maintains dermal collagen (type I and III) and hyaluronic acid. Withdrawal → ↓ collagen by ~2%/year for first 5 years → thin, less elastic skin
Hair	Thinning of scalp hair, increase in facial hair	Relative androgen excess (adrenal androgens unopposed by declining oestrogen) → androgenic hair pattern
Joints	Arthralgia, stiffness	Oestrogen has anti-inflammatory effects on synovium; also maintains cartilage proteoglycans
Cognition	Subjective memory complaints	Oestrogen effects on hippocampal cholinergic neurons; however, HRT has not been shown to prevent dementia (WHI)
Body composition	↑ total body fat, ↑ central adiposity, ↓ lean muscle mass	Loss of oestrogen's partitioning effect on fat storage; sarcopenia accelerated

The STRAW+10 Staging System (Stages of Reproductive Ageing Workshop)

This is the internationally accepted classification (updated 2012) for staging reproductive ageing. It defines the menopause transition using menstrual cycle criteria and supportive biomarkers.

Stage	Name	Menstrual Criteria	FSH	Other Features
–5	Early reproductive	Regular cycles	Normal	Peak fertility
–4	Peak reproductive	Regular cycles	Normal	Peak fertility
–3b	Late reproductive	Regular cycles, subtle ↓ cycle length	Normal–↑	↓ AMH, ↓ antral follicle count
–2	Early menopausal transition	↑ variability (≥7 days change in cycle length)	↑ variable	Vasomotor symptoms begin
–1	Late menopausal transition	≥2 skipped cycles, ≥60 days amenorrhoea	↑↑ (> 25 IU/L)	Most symptomatic phase
0	Final Menstrual Period (FMP)	—	—	Retrospective diagnosis
+1a	Early postmenopause (first 2y)	Amenorrhoea	↑↑↑	Rapid bone loss begins
+1b	Early postmenopause (next 3–6y)	Amenorrhoea	Stabilising high	Continued bone loss
+2	Late postmenopause	Amenorrhoea	↑ stable	Urogenital atrophy predominates

7. Clinical Features — Symptoms and Signs

Let me organise the clinical features systematically by time course (as they would present to a clinician), with pathophysiological explanations inline.

7a. Symptoms

Symptom	Pathophysiological Basis
Hot flushes	Oestrogen withdrawal narrows hypothalamic thermoneutral zone → inappropriate heat-dissipation response (vasodilation, sweating) to minor core temperature fluctuations (via KNDy neurons/NK3 pathway)
Night sweats	Same as hot flushes occurring during sleep → disrupt sleep architecture
Palpitations	Sympathetic activation during vasomotor episodes; also ↓ oestrogen effect on cardiac ion channels (some studies suggest oestrogen withdrawal ↑ supraventricular ectopics)
Dizziness	Transient peripheral vasodilation during flushes → ↓ BP → orthostatic sensation
Menstrual irregularity	Anovulatory cycles (insufficient follicle maturation → no LH surge → no ovulation → no progesterone → erratic endometrial shedding); variable cycle length, oligomenorrhoea, eventually amenorrhoea
Irritability, mood swings, anxiety	Fluctuating oestrogen → unstable serotonergic/noradrenergic neurotransmission
Depression	↓ Oestrogen → ↓ serotonin synthesis + psychosocial stressors of life stage
Loss of energy and drive	Multifactorial: ↓ oestrogen neurotrophic effects, poor sleep, mood disturbance
Loss of concentration	Oestrogen supports hippocampal and prefrontal cortical cholinergic function → withdrawal impairs attention and working memory
Sleep disturbance	Nocturnal vasomotor episodes; loss of progesterone (GABAergic/sedative); ↓ oestrogen effect on sleep-regulating centres
Decreased libido	↓ Testosterone (ovarian contribution declines), ↓ oestrogen-mediated genital sensitivity, dyspareunia-related avoidance, psychological factors
Dyspareunia	Vaginal atrophy → thinning/dryness → friction → pain during intercourse

Symptom	Pathophysiological Basis
Vaginal dryness, burning, pruritus	Atrophy of oestrogen-dependent vaginal epithelium → loss of glycogen → ↓ Lactobacillus → ↑ pH → inflammation
Urinary urgency, frequency	Oestrogen receptor–rich bladder trigone and urethra atrophy → altered detrusor sensitivity → overactive bladder symptoms
Dysuria	Urethral mucosal atrophy mimics UTI (atrophic urethritis); also ↑ true UTI risk
Recurrent UTIs	↑ Vaginal pH → loss of protective Lactobacillus → colonisation by uropathogens (E. coli); thinned urethral mucosa ↓ barrier function
Stress urinary incontinence	↓ Urethral closure pressure from urethral mucosal and submucosal atrophy + pelvic floor weakening
Skin dryness, thinning	↓ Dermal collagen and hyaluronic acid
Joint pains/stiffness	Loss of oestrogen's anti-inflammatory effects on synovium and cartilage

Symptom/Condition	Pathophysiological Basis
Fragility fractures (vertebral, hip, distal radius)	Postmenopausal osteoporosis: ↑ RANKL:OPG → ↑ osteoclast activity → net bone loss → ↓ BMD
Height loss, kyphosis	Vertebral compression fractures from weakened trabecular bone
Cardiovascular events (MI, stroke)	Loss of oestrogen's vasculoprotective effects (endothelial NO, lipid profile, insulin sensitivity)
Pelvic organ prolapse	Progressive loss of pelvic floor collagen + connective tissue weakening
Cognitive decline (uncertain)	Oestrogen effects on hippocampal neurons; however, causation vs. association remains debated

Sign	What You're Looking For	Pathophysiological Basis
Flushing	Visible erythema of face, neck, upper chest during a hot flush	Peripheral vasodilation (cutaneous arteriolar dilation) mediated by thermoregulatory centre
Diaphoresis	Sweating during/after a flush	Eccrine gland activation as heat-dissipation mechanism
Tachycardia	↑ HR during a vasomotor episode	Sympathetic activation
Vaginal atrophy on examination	Pale, thin, dry vaginal mucosa; loss of rugae; petechiae; narrowing of introitus	Oestrogen deficiency → epithelial thinning, ↓ vascularity
↑ Vaginal pH (> 5.0)	Measured with pH paper on speculum exam	↓ Glycogen → ↓ Lactobacillus → ↓ lactic acid production
Cervical changes	Cervix may appear flush with vaginal vault; os may be stenotic	Atrophy
Dry vulvar skin	Thin, pale, possibly labial fusion in severe cases	Vulvar skin oestrogen-dependent; atrophy without oestrogen
Urethral caruncle	Small, red, fleshy protrusion at urethral meatus	Prolapse of urethral mucosa due to oestrogen-dependent mucosal atrophy
Signs of osteoporosis	Thoracic kyphosis ("dowager's hump"), loss of height, tenderness over vertebral fracture site	Vertebral compression fractures
Central obesity	↑ Waist circumference, waist-to-hip ratio	Shift from peripheral to central fat distribution without oestrogen

Premature Ovarian Insufficiency (POI) — A Special Category

Since POI causes the same pathophysiology as menopause but at a younger age (< 40), the consequences are more severe and prolonged:

Greater cumulative bone loss → higher lifetime fracture risk.
Greater cardiovascular risk accumulation.
Infertility at a reproductively active age → psychological distress.
HRT is essential (not optional) and should be continued at least until the average age of menopause (51).

High Yield Summary

Definitions (must know for exams):

Climacteric = years of waning ovarian function (the transitional era)
Menopause = permanent cessation of ovarian function; the last menstrual period, diagnosed retrospectively after 12 months amenorrhoea
Perimenopause = from first signs of approaching menopause to 12 months after FMP
POI = menopause before age 40

Pathophysiology (the central cascade): Follicular depletion → ↓ inhibin B → ↑ FSH (earliest change) → ↓ oestradiol → loss of negative feedback → ↑↑ FSH/LH → hypergonadotropic hypogonadism

The Four Pillars of Climacteric Symptoms:

Vasomotor (hot flushes, sweats, palpitations, dizziness) — narrowed thermoneutral zone via KNDy neurons
Psychological (mood changes, insomnia, poor concentration) — ↓ serotonin/noradrenaline; bio-psycho-social
Urogenital (vaginal dryness, recurrent UTI, incontinence) — progressive, does NOT self-resolve
Sexual (dyspareunia, ↓ libido) — multifactorial

Long-term Consequences:

Osteoporosis (↑ RANKL:OPG → ↑ bone resorption; most rapid in first 5–7 years)
Cardiovascular disease (loss of oestrogen's vasculoprotective and lipid effects → #1 killer postmenopause)

Postmenopausal oestrogen source: Oestrone (E1) from peripheral aromatisation of adrenal androgens in adipose tissue (NOT oestradiol from ovary)

Postmenopausal hormone profile: ↑↑ FSH, ↑ LH, ↓↓ E2, ↓ inhibin B, undetectable AMH

Active Recall - Climacteric Symptoms and Menopause

^[1] Lecture slides: Block C - Climacteric symptoms_ menopause and related illness; amenorrhoea.pdf (p16–19) ^[2] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (p32, p39–40) ^[3] Senior notes: Adrian Lui Gynecology Notes.pdf ^[4] Senior notes: Ryan Ho Endocrine.pdf (p47–48, p110–112) ^[5] Senior notes: Maksim Medicine Notes.pdf (p109)

Differential Diagnosis of Climacteric Symptoms

Here's the clinical reality: a 50-year-old woman walks into your clinic saying "I'm having hot flushes, I can't sleep, I feel anxious, and my periods have stopped." Your reflex is "menopause." But a good clinician asks: what else could mimic this picture?

Climacteric symptoms are a clinical syndrome — they are not pathognomonic of menopause. Several conditions share overlapping features (vasomotor instability, mood disturbance, menstrual irregularity, palpitations, weight changes). Missing a thyrotoxic storm because you assumed "it's just the menopause" would be a serious error.

The lecture slides specifically highlight this:

D/dx: thyrotoxicosis, anxiety symptoms ^[3]

Let's work through the differential diagnosis systematically, organised by the symptom cluster that most closely overlaps.

I find it most useful to think about the differential by asking: which symptom cluster is dominant? Then consider mimics of each.

1. Differential Diagnosis of Vasomotor Symptoms

These are the conditions that can present with flushing, sweating, palpitations, and heat intolerance — mimicking menopausal hot flushes.

This is the #1 differential the lecture slides want you to know.

Feature	Menopause	Thyrotoxicosis
Heat intolerance	Episodic flushes (2–4 min), then resolves	Constant, not episodic
Sweating	With flushes, often nocturnal	Generalised, persistent
Weight	May gain (central adiposity)	Weight loss despite good appetite ^[5]
Appetite	Normal or mildly decreased	Increased
Bowel habit	Normal or constipation (age-related)	Diarrhoea ^[5]
Heart rate	Episodic tachycardia with flushes	Persistent tachycardia, may have AF ^[5]
Tremor	Usually absent	Fine resting tremor
Eyes	Normal	Lid retraction, lid lag (± Graves' ophthalmopathy)
Menstruation	Oligomenorrhoea → amenorrhoea	Amenorrhoea or oligomenorrhoea ^[5] (thyroid hormone excess suppresses GnRH pulsatility)
Skin	Dry, thin (oestrogen-deprived)	Warm, moist, shiny ^[5]
Mood	Fluctuating, depressed	Agitated, irritable ^[5]

Why the confusion? Both conditions cause sympathetic-like activation (sweating, palpitations, heat intolerance) and can cause amenorrhoea. However, thyrotoxicosis produces constant hypermetabolism, whereas menopausal flushes are episodic (sudden onset, last 2–4 minutes, then resolve).

Investigation to distinguish: TFT (TSH ↓, free T4/T3 ↑ in thyrotoxicosis; TSH normal in menopause).

Exam Pearl

Never diagnose menopause without at least checking TFTs. Thyrotoxicosis in a middle-aged woman is extremely common (Graves' disease peaks in women aged 40–60) and presents with overlapping symptoms. The lecture slides specifically flag this as a differential.

A rare but dangerous mimic. Produces episodic (paroxysmal) symptoms — which makes it closer to menopausal flushes in character than thyrotoxicosis.

D/dx of episodic sweating and/or flushing: oestrogen/testosterone deficiency (e.g. menopause, castration), carcinoid syndrome, phaeochromocytoma (sweat but do not flush), thyrotoxicosis, systemic mastocytosis, allergy ^[6]

Feature	Menopause	Phaeochromocytoma
Flushing	Yes (vasodilation)	Pallor — not flushing (catecholamine-induced vasoconstriction) ^[6]. The classic teaching: "phaeochromocytoma sweats but does NOT flush"
Hypertension	Modest postmenopausal ↑	Severe paroxysmal or sustained HTN (hallmark)
Headache	Not typical	Severe, pounding (hypertensive)
Palpitations	Episodic with flushes	Severe, with tremor
Anxiety/fear	Chronic, mood-related	Acute, intense sense of impending doom during attacks

Key distinguishing feature: The 5 Ps — Pressure (HTN), Pain (headache), Palpitation, Perspiration, Pallor ^[6]. The pallor (not flushing) is the clinical giveaway.

Why pallor? Catecholamines (noradrenaline/adrenaline) cause α1-mediated peripheral vasoconstriction → skin is pale and cool (the opposite of menopausal vasodilation/flushing).

Investigation: 24-hour urine fractionated metanephrines or plasma fractionated metanephrines ^[6].

Serotonin-producing neuroendocrine tumours (usually GI, with hepatic metastases allowing serotonin to bypass hepatic first-pass metabolism).

Feature	Menopause	Carcinoid
Flushing	Upper body, episodic	Flushing (similar distribution, but may be more prolonged and cyanotic)
Diarrhoea	Not typical	Secretory diarrhoea (serotonin stimulates intestinal motility)
Wheeze	No	Bronchoconstriction (serotonin/histamine)
Cardiac	Palpitations	Right-sided valvular disease (carcinoid heart — tricuspid regurgitation, pulmonary stenosis)

Investigation: 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid, the serotonin metabolite).

Mast cell proliferation → episodic histamine release → flushing, urticaria, pruritus, hypotension, GI symptoms. Distinguished by urticaria pigmentosa (brown macules on skin with positive Darier sign — wheal on stroking).

Investigation: Serum tryptase.

Anxiety symptoms are specifically listed as a differential in the lecture slides ^[3].

Feature	Menopausal flushes	Panic attacks
Trigger	Spontaneous (often warmth, stress)	Unpredictable, or triggered by situations ^[8]
Duration	2–4 minutes	10–30 minutes typically
Core experience	Warmth/heat, sweating	Intense fear, sense of losing control, fear of dying ^[8]
Palpitations	Yes	Yes — prominent ^[8]
Paraesthesiae	Unusual	Common (hyperventilation → respiratory alkalosis → ↓ ionised Ca²⁺) ^[8]
Derealization	No	May occur ^[8]
Chest pain	Uncommon	Common ^[8]
Anticipatory anxiety	Minimal	Persistent concern about further attacks ^[8]

Why the overlap? Both involve sympathetic activation. But panic disorder has a prominent cognitive component (catastrophic thoughts, fear of dying) that menopausal flushes lack. Also, menopausal flushes are characterised by objective peripheral warmth and visible flushing, which panic attacks generally lack.

Important nuance: Bio-psycho-social factors ^[1] — the perimenopause can precipitate panic attacks or worsen pre-existing anxiety. Both diagnoses can coexist.

Several medications cause flushing that mimics menopausal vasomotor symptoms:

Niacin (nicotinic acid) — prostaglandin-mediated vasodilation
Calcium channel blockers — vasodilation
Nitrates — vasodilation
Tamoxifen/Aromatase inhibitors — anti-oestrogenic effect
GnRH agonists — iatrogenic medical menopause (this is expected, not a mimic)
Opioid withdrawal

When a 45–55-year-old woman presents with amenorrhoea, menopause is the most likely cause — but you must exclude other pathology.

Golden Rule

Always exclude pregnancy first — even in a 50-year-old woman. It is the #1 cause of secondary amenorrhoea at any age, and missing it is indefensible.

Systematic approach to secondary amenorrhoea (from the HPO axis top-down) ^[5]^[7]:

Level	Cause	Key Features	How to Distinguish
Physiological	Pregnancy	Amenorrhoea + nausea + breast tenderness	β-hCG (urine or serum)
Physiological	Menopause	Age 45–55, vasomotor symptoms, gradual onset	FSH > 30 IU/L on two occasions ≥ 4–6 weeks apart (supportive, not diagnostic; ↑FSH should NOT be taken as diagnostic because it rises some years before menopause ^[3])
Hypothalamic	Functional hypothalamic amenorrhoea	Stress, excessive exercise, low BMI, eating disorders	Low/normal FSH, low LH, low E2; diagnosis of exclusion
Hypothalamic	Kallmann syndrome	Primary amenorrhoea with anosmia (unlikely first presentation at this age)	MRI brain, olfactory testing
Pituitary	Hyperprolactinaemia ^[5]^[7]	Galactorrhoea, visual field defects if macroadenoma; causes: prolactinoma, drugs (antipsychotics, metoclopramide, domperidone), hypothyroidism, stalk effect	Serum prolactin, MRI pituitary
Pituitary	Hypopituitarism	G > F > A > T axis failure order ^[7]; fatigue, ↓ libido, ↓ body hair	Pituitary profile (FSH, LH, TSH, ACTH, cortisol, IGF-1, prolactin), MRI pituitary
Thyroid	Hypothyroidism ^[5]	Cold intolerance, weight gain, constipation, bradycardia, menorrhagia (can cause amenorrhoea too, but menorrhagia more classic)	TSH ↑, fT4 ↓
Thyroid	Hyperthyroidism	Heat intolerance, weight loss, tremor, oligomenorrhoea/amenorrhoea	TSH ↓, fT4/fT3 ↑
Ovarian	PCOS	Oligomenorrhoea, hyperandrogenism (acne, hirsutism), obesity, insulin resistance	Rotterdam criteria (2 of 3: oligo/anovulation, hyperandrogenism, polycystic ovaries on USS)
Ovarian	Premature ovarian insufficiency (POI)	Menopause-like picture but age < 40	FSH > 25 IU/L on 2 occasions ≥ 4 weeks apart in a woman < 40 with amenorrhoea ≥ 4 months
Adrenal	Cushing's syndrome ^[7]	Moon face, buffalo hump, striae, proximal myopathy, oligo/amenorrhoea	24h urine cortisol, overnight dexamethasone suppression test
Adrenal	Congenital adrenal hyperplasia (late-onset)	Hyperandrogenism, virilisation, primary amenorrhoea in severe forms	17-hydroxyprogesterone
Uterine	Asherman syndrome ^[5]	Amenorrhoea following uterine instrumentation (D&C, endometrial ablation); normal hormones	Hysteroscopy (gold standard) showing intrauterine adhesions

When a perimenopausal woman presents primarily with low mood, anxiety, or insomnia, consider:

Diagnosis	Key Distinguishing Feature
Climacteric mood changes	Temporally linked to vasomotor symptoms and menstrual irregularity; mood fluctuates (not persistently low); responds to HRT
Major depressive disorder ^[9]	Persistent low mood ≥ 2 weeks meeting diagnostic criteria; anhedonia as core feature; does not necessarily correlate with menopausal transition; may need antidepressants
Generalised anxiety disorder (GAD) ^[8]^[10]	Free-floating anxiety that is persistent, NOT restricted to particular circumstances ^[10]; somatic symptoms (muscle tension, GI upset); would NOT be episodic like menopausal flushes
Adjustment disorder ^[9]	Onset ≤ 3 months of identifiable stressor; does not meet full criteria for depressive or anxiety disorder ^[9] — common in perimenopause given life changes
Hypothyroidism	Fatigue, weight gain, cognitive slowing — overlaps with depressive-type climacteric symptoms; check TFTs
Obstructive sleep apnoea	Sleep disturbance with daytime somnolence; weight gain around menopause may precipitate; partner reports snoring/apnoeas

Clinical Tip

The perimenopause is a time of increased vulnerability to first-episode or recurrent depression — risk is approximately 2–4× higher than premenopause. Both hormonal and psychosocial factors contribute. If a woman meets criteria for major depressive disorder, treat it as such (antidepressants ± psychotherapy). HRT alone is insufficient for true clinical depression, though it may augment antidepressant response.

Diagnosis	Key Distinguishing Feature
GSM (menopausal urogenital atrophy)	Progressive; vaginal pH > 5; pale thin mucosa on exam; responds to topical oestrogen
Vulvovaginal candidiasis	Pruritus + thick white discharge; KOH prep shows hyphae/pseudohyphae; pH ≤ 4.5
Bacterial vaginosis	Thin grey-white discharge, fishy odour; clue cells on wet mount; pH > 4.5
Lichen sclerosus	White, crinkled "cigarette paper" skin; labial fusion; intense pruritus; biopsy diagnostic; risk of vulvar SCC
Contact dermatitis	Linked to soap, detergent, lubricant exposure; pruritic, erythematous; history-dependent
Vulvar/vaginal malignancy	Postmenopausal bleeding, mass, ulceration; biopsy essential
Overactive bladder (OAB)	Urgency/frequency without atrophy signs; may coexist with GSM but also occurs independently
UTI	Dysuria + frequency but with pyuria/bacteriuria on MSU; GSM increases UTI risk, so they coexist

Climacteric Feature Mimicked	Differential Diagnoses	Key Discriminator
Hot flushes / sweating	Thyrotoxicosis ^[3], phaeochromocytoma, carcinoid, mastocytosis, panic disorder, drugs	TFTs, 24h urine metanephrines, 5-HIAA, tryptase, psychiatric assessment
Amenorrhoea	Pregnancy, hypothalamic amenorrhoea, PCOS, hyperprolactinaemia, thyroid disease, POI, Asherman, Cushing's	β-hCG, FSH/LH/E2, prolactin, TFTs, USS pelvis, cortisol
Mood disturbance	MDD, GAD, adjustment disorder, hypothyroidism, OSA	Psychiatric criteria, TFTs, sleep study
Palpitations	AF, SVT, phaeochromocytoma, thyrotoxicosis, anaemia, anxiety	ECG, Holter, TFTs, CBC, metanephrines
Vaginal dryness / dyspareunia	Candidiasis, BV, lichen sclerosus, contact dermatitis, malignancy	Vaginal pH, swabs, biopsy if indicated
Recurrent UTI / urinary symptoms	True UTI, OAB, interstitial cystitis, urethral diverticulum	MSU culture, urodynamics
Osteoporosis	Secondary causes: hyperparathyroidism, Cushing's, myeloma, hyperthyroidism, CKD, drugs (steroids, PPIs)	Ca/PO4, PTH, cortisol, SPEP, TFTs, RFTs, DEXA

When you see a woman aged 40–55 presenting with a combination of amenorrhoea, vasomotor symptoms, and mood changes:

Must-Know for Exams

The lecture slides emphasise two specific differentials for climacteric symptoms: thyrotoxicosis and anxiety symptoms ^[3]. These are the ones most likely to appear in an OSCE or SAQ. Always check TFTs and always consider psychiatric comorbidity.

POI (menopause < 40) is pathological and demands investigation for an underlying cause, unlike natural menopause:

Feature	Natural Menopause	POI
Age	45–55 (mean 51)	< 40
FSH	↑↑	↑↑ (same hormonal picture)
Karyotype	Not indicated	Must check — Turner syndrome (45,X), Fragile X premutation
Autoimmune screen	Not routine	Indicated — anti-adrenal Ab, anti-TPO Ab (associated autoimmune conditions)
Bone density	Screen based on risk factors	Early DEXA mandatory (longer duration of oestrogen deficiency)
HRT	Symptom-dependent	Essential — continue until at least age 51 to replace "missing" physiological oestrogen

High Yield Summary

Key differentials to remember (exam-tested):

Thyrotoxicosis — #1 differential for vasomotor symptoms; constant hypermetabolism vs. episodic flushes; ALWAYS check TFTs ^[3]
Pregnancy — #1 differential for amenorrhoea at ANY age; ALWAYS do β-hCG before anything else
Anxiety/panic disorder — overlapping palpitations, sweating, insomnia; look for cognitive component (catastrophic thinking, fear of dying) vs. pure warmth/flushing in menopause ^[3]
Phaeochromocytoma — episodic sweating but PALLOR (not flushing) + severe HTN; "sweats but does not flush" ^[6]
Hyperprolactinaemia — amenorrhoea + galactorrhoea; check prolactin ^[5]
PCOS — irregular periods + hyperandrogenism; but usually presents younger
Secondary causes of osteoporosis — always consider if Z-score ≤ –2.0

The diagnostic approach: β-hCG → TFTs → FSH/LH/E2 → prolactin → consider further investigations based on findings.

Menopause remains a clinical diagnosis (retrospective: 12 months amenorrhoea in a woman of appropriate age). ↑FSH should NOT be taken as diagnostic because it rises some years before menopause ^[3].

Active Recall - Differential Diagnosis of Climacteric Symptoms

References

^[1] Lecture slides: Block C - Climacteric symptoms_ menopause and related illness; amenorrhoea.pdf (p18–19) ^[2] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (p39–40) ^[3] Senior notes: Adrian Lui Gynecology Notes.pdf (p32) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p47–48) ^[5] Senior notes: Maksim Medicine Notes.pdf (p79, p90, p107) ^[6] Senior notes: Ryan Ho Endocrine.pdf (p66) ^[7] Senior notes: Ryan Ho Endocrine.pdf (p110–112) ^[8] Senior notes: Ryan Ho Psychiatry.pdf (p179) ^[9] Senior notes: Ryan Ho Psychiatry.pdf (p140) ^[10] Senior notes: Ryan Ho Psychiatry.pdf (p170, p173)

Diagnostic Criteria, Algorithm and Investigations for Climacteric Symptoms and Menopause

Before diving into investigations, let's establish the most important concept:

Menopause is the permanent cessation of ovarian function and fertility — a specific event (the final menstrual period) — diagnosed retrospectively after cessation of menses for 12 months in a previously cycling woman ^[1].

This means there is no single blood test that "diagnoses" menopause. It is a clinical, retrospective diagnosis. The role of investigations is primarily to:

Exclude differentials (especially pregnancy, thyroid disease, hyperprolactinaemia).
Confirm the diagnosis in ambiguous cases (e.g., prior hysterectomy, premature presentation).
Screen for long-term consequences (osteoporosis, cardiovascular risk).
Investigate underlying aetiology when menopause occurs prematurely (POI).

1. Diagnostic Criteria

There is no formal "diagnostic criteria" in the way we have for, say, rheumatoid arthritis. Instead, the diagnosis rests on:

Criterion	Detail
Age	Typically 45–55 years (median 51)
Amenorrhoea duration	≥ 12 consecutive months without menstruation ^[1]^[3]
No other pathological or physiological cause	Must exclude pregnancy, thyroid disease, hyperprolactinaemia, PCOS, Asherman syndrome, etc. ^[3]
Clinical context	Symptoms consistent with oestrogen deficiency (vasomotor, urogenital, psychological — though not required for diagnosis)

Critical Exam Point

↑FSH should NOT be taken as diagnostic because it rises some years before menopause ^[3]. A single elevated FSH in a 48-year-old with irregular periods does NOT mean she is menopausal — she may still ovulate and even conceive. FSH fluctuates wildly in perimenopause. Do not use FSH to "diagnose" menopause in women aged 45+ with typical symptoms.

When IS hormone testing useful for diagnosing menopause?

According to NICE guidelines (NG23, updated 2024) and current clinical practice:

Scenario	Do You Need FSH?	Rationale
Woman ≥ 45 with typical symptoms + ≥ 12 months amenorrhoea	No — clinical diagnosis	Classical presentation; testing adds no value and may confuse
Woman aged 40–45 with menopausal symptoms	Consider FSH	Earlier than expected; FSH helps support the diagnosis (FSH > 30 IU/L on two occasions ≥ 4–6 weeks apart suggests ovarian failure)
Woman < 40 with suspected POI	Yes — essential	POI is pathological; requires biochemical confirmation (FSH > 25 IU/L on two occasions ≥ 4 weeks apart) + further aetiological workup
Woman with prior hysterectomy (uterus removed but ovaries retained)	Consider FSH	No menstrual periods to use as a clinical marker; need biochemical evidence of ovarian failure
Woman on hormonal contraception	Cannot rely on FSH	Exogenous hormones suppress/alter FSH; need to stop hormonal method and reassess (or measure FSH in the pill-free interval of CHC — though this is unreliable)

POI has specific diagnostic criteria because it is a pathological condition requiring investigation:

Criterion	Detail
Age	< 40 years
Amenorrhoea/oligomenorrhoea	≥ 4 months
Elevated FSH	> 25 IU/L on two occasions ≥ 4 weeks apart (ESHRE 2024 guideline)

Why two occasions? Because FSH fluctuates in the perimenopausal window — a single elevated reading could be a transient peak during an anovulatory cycle. Repeating it 4 weeks later confirms persistent ovarian failure rather than a temporary fluctuation.

There are no universally accepted formal "diagnostic criteria" for perimenopause. The STRAW+10 staging system provides a framework (discussed in Part 1). In practice:

Early perimenopause: menstrual cycle variability ≥ 7 days difference in consecutive cycle lengths (e.g., one cycle 24 days, next cycle 35 days).
Late perimenopause: ≥ 2 skipped cycles with ≥ 60 days of amenorrhoea between periods.
Supportive: vasomotor symptoms + FSH > 25 IU/L (if measured), but clinical features are usually sufficient.

Here is a comprehensive diagnostic algorithm for a woman presenting with suspected climacteric symptoms:

3. Investigation Modalities — Detailed Interpretation

Let me walk through each investigation systematically: what it measures, why we order it, and how to interpret the results.

3a. First-Line Investigations (for all women presenting with suspected menopause)

Parameter	Detail
What it measures	Human chorionic gonadotrophin, produced by trophoblastic cells after implantation
Why	Always exclude pregnancy first — amenorrhoea in a reproductive-age woman is pregnancy until proven otherwise
Interpretation	Positive = pregnant (even perimenopausal women can conceive). Negative = proceed to further evaluation
Pitfall	Very early pregnancy may have negative urine hCG; if clinical suspicion high, repeat or use serum quantitative hCG

Parameter	Detail
What it measures	TSH (pituitary feedback marker), free T4, ± free T3
Why	D/dx: thyrotoxicosis ^[3] — the #1 differential for vasomotor symptoms. Hypothyroidism can also cause amenorrhoea, fatigue, weight gain, and mood disturbance
Interpretation

Pattern	Diagnosis	Relevance to Menopause DDx
TSH ↓, fT4 ↑ (± fT3 ↑)	Hyperthyroidism	Mimics vasomotor symptoms; causes amenorrhoea via suppression of GnRH pulsatility
TSH ↑, fT4 ↓	Primary hypothyroidism	Mimics psychological symptoms (fatigue, depression, poor concentration); can cause menorrhagia OR amenorrhoea; ↑TRH can cause secondary hyperprolactinaemia ^[7]
Normal	Thyroid disease excluded	Proceed

Why does hypothyroidism cause amenorrhoea? Two mechanisms: (1) ↑TRH → ↑prolactin → suppresses GnRH → hypogonadotropic hypogonadism ^[7]; (2) Altered SHBG and peripheral oestrogen metabolism.

Parameter	Detail
What it measures	FSH and LH from anterior pituitary gonadotroph cells
Why	To confirm ovarian failure (hypergonadotropic hypogonadism) and distinguish from hypothalamic/pituitary causes (hypogonadotropic hypogonadism)
When to order	Women < 45 with suspected menopause; women < 40 with suspected POI; post-hysterectomy; ambiguous clinical picture
When NOT needed	Women ≥ 45 with classic symptoms and ≥ 12 months amenorrhoea ^[3]

Interpretation:

FSH Level	LH Level	E2 Level	Interpretation
↑↑ (> 30–40 IU/L)	↑	↓↓	Hypergonadotropic hypogonadism = ovarian failure (menopause/POI). The ovary has failed → no negative feedback → FSH/LH rise
Normal or ↓	Normal or ↓	↓	Hypogonadotropic hypogonadism = hypothalamic or pituitary cause (functional hypothalamic amenorrhoea, hyperprolactinaemia, Sheehan syndrome, etc.)
Normal	↑ (LH:FSH > 2–3:1)	Normal or ↑	Suggests PCOS (high LH drives theca cell androgen production; FSH relatively suppressed)
Variable / fluctuating	Variable	Variable	Perimenopause — hormones are in flux; a single measurement is unreliable

Why FSH Rises Before LH

Inhibin B (from granulosa cells) selectively suppresses FSH but NOT LH. As follicle numbers decline, inhibin B falls first → FSH rises first (loss of selective brake). LH only rises significantly later when oestradiol drops enough to remove negative feedback at the hypothalamic-pituitary level. This is why FSH is the earlier and more dramatic change.

Practical tip: For POI diagnosis, repeat FSH ≥ 4 weeks apart because perimenopause involves wild fluctuations. A single elevated FSH is not definitive.

Parameter	Detail
What it measures	The primary ovarian oestrogen (17β-oestradiol)
Why	Confirms oestrogen deficiency in conjunction with FSH; helps distinguish perimenopause (fluctuating E2) from postmenopause (persistently low E2)
Interpretation	Postmenopausal E2 typically < 70–110 pmol/L (< 20–30 pg/mL). Perimenopausal E2 is erratic — may be normal, high, or low in any given cycle

Parameter	Detail
What it measures	Serum prolactin level
Why	Hyperprolactinaemia causes secondary amenorrhoea, anovulation, and climacteric symptoms ^[5]^[7] — it is a treatable cause that must be excluded
Interpretation (from senior notes) ^[5]^[7]:

Level (mU/L)	Interpretation
< 500	Normal ^[5]
500–1000	Stress, drugs ^[5]
1000–5000	Drugs, microprolactinoma, disconnection prolactinoma ^[7]
> 5000	Highly suggestive of macroprolactinoma ^[5]^[7]
> 100,000	Potential for high-dose hook effect (false negative) ^[7] — order serial dilutions

What is the hook effect? At very high prolactin concentrations, the analyte saturates both the capture and detection antibodies in a sandwich immunoassay, preventing "sandwich" formation → paradoxically low/normal reading. Solution: run the assay at serial dilutions.

If prolactin elevated → MRI pituitary to look for adenoma ^[5].

3b. Second-Line Investigations — For Specific Clinical Scenarios

Parameter	Detail
Why	Assess endometrial thickness (if abnormal bleeding); ovarian morphology (polycystic ovaries in PCOS); antral follicle count (marker of ovarian reserve)
Key findings

Finding	Interpretation
Thin endometrium (< 4–5 mm in postmenopausal woman)	Atrophic endometrium — consistent with oestrogen deficiency; reassuring if postmenopausal bleeding (PMB)
Thickened endometrium (> 4 mm in PMB)	Concerning for endometrial pathology (hyperplasia, polyp, carcinoma) — requires endometrial sampling
Polycystic ovarian morphology (≥ 12 follicles per ovary or ovarian volume > 10 mL)	Suggestive of PCOS (but can be normal variant)
Small, atrophic ovaries with few/no antral follicles	Consistent with menopause/POI

Parameter	Detail
When	Postmenopausal bleeding (PMB); abnormal perimenopausal bleeding not responding to treatment; endometrial thickness > 4 mm on USS in context of PMB
Why	To exclude endometrial cancer/hyperplasia. Any postmenopausal bleeding is endometrial cancer until proven otherwise
Methods	Pipelle biopsy (outpatient, blind — adequate for screening); hysteroscopy + directed biopsy (gold standard — visualises cavity)

Postmenopausal Bleeding Rule

Any bleeding that occurs ≥ 12 months after the final menstrual period = postmenopausal bleeding (PMB) and MUST be investigated to exclude endometrial cancer. This is regardless of amount, duration, or whether the woman is on HRT (though breakthrough bleeding on HRT is common in the first 3–6 months). Do not dismiss PMB as "just hormones."

Parameter	Detail
What it measures	Bone mineral density (BMD) at lumbar spine and hip (the two most common fracture sites) ^[4]^[11]
Why	Oestrogen deficiency leads to bone loss. Postmenopausal osteoporosis as an important risk factor for fracture ^[1]
When to order	Postmenopausal women with risk factors for osteoporosis; all women with POI; women ≥ 65 (universal screening in some guidelines); before/during HRT to monitor response
Interpretation ^[4]^[11]:

Score	Definition	Clinical Meaning
T-score ≥ –1.0	Normal ^[11]	No treatment needed beyond lifestyle
T-score –1.0 to –2.5	Osteopenia ^[11]	Intermediate risk; consider FRAX score to assess fracture probability
T-score ≤ –2.5	Osteoporosis ^[11]	Treatment indicated
T-score ≤ –2.5 + fragility fracture	Severe (established) osteoporosis ^[11]	Aggressive treatment mandatory

T-score vs Z-score ^[11]:

T-score: compares to peak bone mass of a 30-year-old woman of same sex and ethnicity. Used in postmenopausal women and men ≥ 50.
Z-score: compares to age-matched population. Used in premenopausal women and men < 50. If Z-score ≤ –2.0 → suspect secondary cause ^[11].
FRAX score: 10-year fracture risk calculator incorporating BMD + clinical risk factors. Limitation: only validated for > 40 or postmenopausal women ^[11].

Investigation	Rationale
Fasting lipid profile	Oestrogen probably protective to vasculature and has favourable effect on lipid profile ^[1] — after menopause, LDL ↑, HDL ↓, TG ↑
Fasting glucose / HbA1c	Insulin resistance increases postmenopause; screen for diabetes
Blood pressure	Modest rise in BP postmenopause
BMI / waist circumference	Central adiposity increases cardiovascular risk

When menopause occurs < 40, a directed aetiological search is essential:

Investigation	What You're Looking For	Rationale
Karyotype	Turner syndrome (45,X) or mosaicism (45,X/46,XX)	Turner is the commonest genetic cause of POI; also check for Y chromosome material (→ gonadectomy if present due to gonadoblastoma risk)
FMR1 gene (Fragile X premutation)	CGG repeat expansion (55–200 repeats)	Fragile X premutation is associated with POI in ~6% of sporadic cases and ~13% of familial cases. Also has implications for genetic counselling (offspring risk of full Fragile X syndrome)
Anti-adrenal antibodies (anti-21-hydroxylase Ab)	Autoimmune adrenalitis	POI may be part of autoimmune polyendocrine syndrome (APS); if positive, screen for Addison's disease (morning cortisol, short Synacthen test)
Anti-TPO antibodies	Autoimmune thyroiditis	Commonly coexists with autoimmune POI (APS type 2)
Anti-ovarian antibodies	Autoimmune oophoritis	Poor sensitivity/specificity; not widely used clinically but may support autoimmune aetiology
Morning cortisol ± short Synacthen test	Adrenal insufficiency	If anti-adrenal Ab positive or clinical suspicion of Addison's
Pelvic USS	Ovarian size, follicle count	Small atrophic ovaries = consistent with POI; if follicles present, may indicate intermittent ovarian function (POI is not always permanent in early stages)
DEXA scan	BMD	Mandatory in POI — longer duration of oestrogen deficiency → greater bone loss risk
Calcium, phosphate, vitamin D	Metabolic bone health	Baseline before starting treatment

Investigation	Context	Key Finding
Anti-Müllerian Hormone (AMH)	Ovarian reserve assessment (mainly fertility context)	Very low/undetectable = depleted follicular pool. Note: NOT used to diagnose menopause per se, but useful for fertility counselling in POI and perimenopause
Vaginal pH	Urogenital symptoms	pH > 5.0 consistent with vaginal atrophy (loss of Lactobacillus); pH < 4.5 suggests adequate oestrogenisation
Vaginal maturation index	Research/specialist use	Ratio of parabasal:intermediate:superficial cells on vaginal cytology. Oestrogen deficiency → ↑ parabasal cells (immature). Rarely used clinically now
Bone turnover markers (CTX, P1NP)	Monitoring treatment response	CTX (C-terminal telopeptide) = bone resorption marker; P1NP (procollagen type I N-terminal propeptide) = bone formation marker. ↓ CTX with anti-resorptive therapy confirms drug response. Not used for diagnosis
ECG	Palpitations as predominant symptom	Rule out arrhythmia (AF, SVT)
Mammogram	Pre-HRT screening; ongoing surveillance	Baseline before starting HRT; then regular screening per local protocol (HK: biennial mammogram for women 44–69 in targeted screening)

While not strictly "investigations," clinicians use validated questionnaires to quantify symptom burden and monitor treatment response:

Tool	What It Measures
Kupperman Menopausal Index (KMI)	Weighted score of 11 menopausal symptoms (hot flushes, paraesthesia, insomnia, nervousness, etc.)
Menopause Rating Scale (MRS)	11-item self-administered questionnaire covering somatic, psychological, and urogenital domains
Greene Climacteric Scale	21-item scale assessing psychological (anxiety, depression), somatic, and vasomotor symptoms
FSFI (Female Sexual Function Index)	19-item questionnaire for sexual function (desire, arousal, lubrication, orgasm, satisfaction, pain)
PHQ-9 / GAD-7	Screening for depression and anxiety respectively — important given the bio-psycho-social nature of climacteric mood symptoms ^[1]^[2]

Scenario	Minimum Investigations
Woman ≥ 45 with typical symptoms + amenorrhoea ≥ 12 months	β-hCG (exclude pregnancy), TFTs (exclude thyroid disease). No FSH needed. Consider lipid profile, fasting glucose, DEXA if risk factors
Woman 40–44 with menopausal symptoms	β-hCG, TFTs, FSH (× 2, ≥ 4–6 weeks apart), E2, prolactin. Consider pelvic USS
Woman < 40 with amenorrhoea ≥ 4 months	Full POI workup: β-hCG, FSH (× 2, ≥ 4 weeks apart), E2, TFTs, prolactin, karyotype, FMR1, autoimmune screen (anti-adrenal Ab, anti-TPO), DEXA, pelvic USS
Woman with prior hysterectomy (ovaries retained)	FSH, E2 (no menstrual marker available), TFTs
Postmenopausal bleeding (PMB)	Transvaginal USS (endometrial thickness) → if > 4 mm or clinical concern: endometrial biopsy/hysteroscopy. Also exclude cervical pathology
Pre-HRT assessment	Mammogram, BP, lipid profile, cervical screening status, personal/family history of breast cancer and VTE

High Yield Summary

Menopause diagnosis:

Clinical and retrospective: ≥ 12 months amenorrhoea in a woman of appropriate age with no other cause
FSH should NOT be taken as diagnostic ^[3] in women ≥ 45 with classic presentation
FSH IS needed when: age < 45, suspected POI (< 40), post-hysterectomy, ambiguous clinical picture

POI diagnostic criteria:

Age < 40 + amenorrhoea ≥ 4 months + FSH > 25 IU/L on two occasions ≥ 4 weeks apart

Hormonal profile of menopause:

↑↑ FSH (> 30–40), ↑ LH, ↓↓ E2, ↓ inhibin B — hypergonadotropic hypogonadism

Key investigations to exclude differentials:

β-hCG (pregnancy), TFTs (thyroid disease), prolactin (hyperprolactinaemia)

DEXA interpretation ^[11]:

Normal: T ≥ –1.0
Osteopenia: T –1.0 to –2.5
Osteoporosis: T ≤ –2.5
Severe: T ≤ –2.5 + fragility fracture
Z-score ≤ –2.0 → suspect secondary cause

PMB rule: Any bleeding ≥ 12 months post-FMP → investigate for endometrial cancer (USS ± biopsy)

Active Recall - Diagnosis and Investigations of Menopause

References

^[1] Lecture slides: Block C - Climacteric symptoms_ menopause and related illness; amenorrhoea.pdf (p18–19) ^[2] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (p3, p38) ^[3] Senior notes: Adrian Lui Gynecology Notes.pdf (p31–32) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p48–49) ^[5] Senior notes: Maksim Medicine Notes.pdf (p107) ^[7] Senior notes: Ryan Ho Endocrine.pdf (p110) ^[11] Senior notes: Maksim Medicine Notes.pdf (p109)

Management of Climacteric Symptoms and Menopause

Before jumping into specific treatments, let's establish the framework that should guide every clinical decision:

Principles ^[3]:

Holistic bio-psycho-social approach for general health of a postmenopausal woman ^[3]
Physiological!: most do not require active treatment ^[3]
Important to deal with menopausal symptoms if any (important as ≥ 1/3 of most women's lifespan spent in postmenopausal years) ^[3]

Think of management as addressing three layers simultaneously:

Symptom relief — vasomotor, psychological, urogenital, sexual
Prevention of long-term consequences — osteoporosis, cardiovascular disease
General health promotion — lifestyle, screening, psychosocial support

The key mantra for HRT is: lowest dose for shortest possible duration for symptom relief ^[3] — with the exception of POI, where HRT is replacement therapy, not treatment.

Lifestyle modifications are the foundation — applicable to every menopausal woman regardless of whether she takes HRT ^[1]^[3].

Modification	Rationale / Mechanism
Air conditioning ^[1]	Keeps ambient temperature low → reduces the trigger for hot flushes (core temp less likely to exceed the narrowed thermoneutral zone)
Dressing in layers ^[1]	Allows rapid removal of clothing during a flush → facilitates heat dissipation and reduces discomfort
Avoiding alcohol and spicy food ^[1]	Both are vasodilators → lower the threshold for triggering flushes by widening peripheral vessels and raising skin temperature
Reducing obesity ^[1]	Adipose tissue is insulating → obese women have MORE severe flushes (they cannot dissipate heat efficiently despite higher peripheral oestrone from aromatisation). Also reduces cardiovascular and metabolic risk
Reducing stress ^[1]	Stress activates the sympathoadrenal axis → amplifies vasomotor and psychological symptoms
Cessation of smoking ^[3]^[12]	Smoking accelerates oestrogen metabolism (induces hepatic CYP1A2) → worsens oestrogen deficiency effects. Also independent CVD and osteoporosis risk factor
Weight-bearing exercise ^[3]^[12]	Mechanical loading stimulates osteoblasts → maintains BMD. Also improves mood (endorphins, serotonin), sleep quality, cardiovascular fitness, and metabolic health
Healthy diet, adequate Ca and vitamin D ^[3]^[12]	Ca (1200 mg/day) and vitamin D (800–1000 IU/day) for postmenopausal women to prevent secondary hyperparathyroidism and support bone mineralisation ^[12]^[4]
Sun exposure ^[4]	Cutaneous vitamin D synthesis (UVB converts 7-dehydrocholesterol → cholecalciferol). Important especially in institutionalised elderly

2. Hormone Replacement Therapy (HRT) — The Cornerstone

HRT replaces the oestrogen (± progesterone) that the ovary no longer produces. It is the most effective treatment for vasomotor symptoms — nothing else comes close for moderate-to-severe hot flushes.

Effective for treatment of severe climacteric symptoms and improves QoL ^[1]

Can prevent or delay bone loss, and reduces both vertebral and non-vertebral fractures ^[1]

Indication	Explanation
Premature menopause (< 40y): for bone and cardiac protection (no extra lifetime risk) ^[3]	POI patients have lost oestrogen decades early — HRT is physiological replacement, not pharmacological treatment. Continue until at least age 51 (average natural menopause). There is no increased lifetime risk because you are simply restoring what should have been there
Symptomatic menopausal patient: only for vasomotor symptoms ± mild mood disorder ^[3]	The primary indication for HRT in natural menopause. Must have bothersome symptoms — not for asymptomatic women
(Menopausal women with established osteoporosis) ^[3]	HRT is effective for osteoporosis but no longer indicated for osteoporosis ALONE ^[4] — use dedicated anti-resorptive agents unless vasomotor symptoms coexist, making HRT a dual-purpose choice
(Hypopituitarism and other endocrine diseases) ^[3]	Gonadotropin deficiency → hypogonadism → same principle as POI: replacement
Atrophic symptoms — topical oestrogen ^[1]	For isolated urogenital symptoms, topical (local) oestrogen is first-line — systemic HRT not needed unless systemic symptoms coexist

Timing: need not await amenorrhoea before starting HRT ^[3] — you can start in the perimenopause if symptoms are bothersome.

The fundamental rule: unopposed oestrogen is dangerous in women without hysterectomy as it can ↑ risk of CA endometrium ^[13]. Oestrogen stimulates endometrial proliferation; without progesterone to induce secretory transformation and shedding, the endometrium undergoes hyperplasia → increased risk of endometrial carcinoma.

Clinical Scenario	Regimen	Rationale
Uterus present, < 2 years since menopause or perimenopausal	Sequential (cyclical) combined HRT: continuous oestrogen + cyclical progestogen for 12–14 days/month	Cyclical progestogen causes a predictable withdrawal bleed — mimics the normal cycle. Used early because continuous combined regimens cause erratic breakthrough bleeding if started too soon
Uterus present, > 2 years since menopause	Continuous combined HRT: continuous oestrogen + continuous progestogen daily	Aims for amenorrhoea (no withdrawal bleed). The endometrium is kept atrophic by constant progestogen. Breakthrough bleeding may occur in first 3–6 months but should settle
No uterus (post-hysterectomy)	Oestrogen-only HRT	No endometrium to protect → progestogen unnecessary (and carries its own risks: breast cancer, mood effects)
Isolated urogenital symptoms	Topical vaginal oestrogen (cream, pessary, ring)	Acts locally on vaginal/urethral epithelium; minimal systemic absorption → does NOT require progestogen even with uterus intact. Can be used alongside systemic HRT if needed

2d. Routes of Administration

Understand the different routes of administering hormone replacement therapy ^[2]

Route	Examples	Advantages	Disadvantages
Oral	Conjugated equine oestrogens (Premarin), oestradiol valerate, micronised 17β-oestradiol	Convenient, widely available, well-studied	First-pass hepatic metabolism → ↑ hepatic production of clotting factors (↑ VTE risk), ↑ SHBG, ↑ TG, ↑ CRP. Not ideal for women with VTE risk, migraine, hypertriglyceridaemia
Transdermal (patch/gel)	Oestradiol patches (25–100 μg), oestradiol gel	Bypasses first-pass effect → lower VTE risk (key advantage), stable serum levels, no effect on TG/SHBG/clotting factors	Skin irritation (patches), variable absorption (gel), less convenient
Vaginal (topical)	Oestriol cream, oestradiol vaginal tablet (Vagifem), oestradiol ring (Estring)	Targeted local effect, minimal systemic absorption, does not need progestogen cover, very safe long-term	Does NOT treat systemic symptoms (vasomotor, bone)

Transdermal vs Oral — Exam Favourite

The transdermal route is preferred when there is increased VTE risk (obesity, smoker, personal/family history of VTE, migraine with aura, hypertriglyceridaemia) because it avoids first-pass hepatic metabolism and therefore does NOT increase clotting factor production. The oral route increases hepatic synthesis of Factor VII, fibrinogen, and CRP → pro-thrombotic.

Progestogen types ^[1]:

Oral ^[1]: medroxyprogesterone acetate (MPA), norethisterone, dydrogesterone, micronised progesterone (Utrogestan)
Mirena® — levonorgestrel-releasing intrauterine system ^[1]: provides endometrial protection locally while minimising systemic progestogen exposure. Particularly useful for women who get progestogenic side effects (mood changes, bloating, breast tenderness) on oral progestogens

Progestogen Type	Notes
Micronised progesterone (Utrogestan)	Closest to natural progesterone; better side-effect profile (less breast tenderness, better lipid profile, may be sedating → take at night → helps insomnia); associated with lower breast cancer risk than synthetic progestogens
MPA	The progestogen used in the WHI trial; associated with higher breast cancer risk than micronised progesterone
LNG-IUS (Mirena)	Local endometrial effect; minimal systemic absorption; can also serve as contraception in perimenopausal women; licensed for endometrial protection in HRT for 5 years

HRT Contraindications ^[1]:

Contraindication	Rationale
Severe liver disease ^[1]	Oestrogen is hepatically metabolised; impaired clearance → accumulation; oral oestrogen ↑ hepatic protein synthesis → worsens portal hypertension/coagulopathy
Cerebrovascular disease ^[1]	HRT (especially oral) associated with slight ↑ stroke risk; avoid in active CVD
Deep vein thrombosis and embolism ^[1]	Oral oestrogen ↑ clotting factors → ↑ VTE risk. Note: transdermal route has minimal/no VTE risk and may be considered with specialist guidance in women with past VTE
Oestrogen-dependent tumours e.g. breast, uterus ^[1]	Oestrogen stimulates proliferation of ER+ cancer cells → risk of recurrence/progression
Undiagnosed uterine bleeding ^[1]	Must exclude endometrial carcinoma before starting HRT — you could mask or worsen malignant bleeding

Additional relative contraindications / cautions (not explicitly on lecture slides but clinically important):

Active or recent arterial thromboembolic disease (MI, stroke)
Untreated endometrial hyperplasia
Known thrombophilia (Factor V Leiden, protein C/S deficiency) — consider transdermal route
Migraine with aura — use transdermal route or avoid systemic HRT
Gallbladder disease — oral oestrogen ↑ cholesterol saturation of bile → ↑ gallstone risk
SLE with antiphospholipid antibodies

Understanding the WHI (Women's Health Initiative, 2002) and subsequent analyses is essential because it shaped — and initially distorted — clinical practice regarding HRT.

Outcome	Effect of Combined HRT	Effect of Oestrogen-Only HRT	Clinical Interpretation
Vasomotor symptoms	↓↓↓ (most effective treatment)	↓↓↓	Primary indication
Fractures	↓ (~34% reduction in hip fracture)	↓ (~39% reduction in hip fracture)	Proven bone protection; can prevent or delay bone loss, and reduces both vertebral and non-vertebral fractures ^[1]
Breast cancer	Slight ↑ risk ^[4] (RR ~1.26 for combined E+P after > 5 years)	No increase (possibly slight decrease)	Risk is attributable to the progestogen component, especially synthetic progestogens. Micronised progesterone may carry lower risk
Endometrial cancer	Neutral (progestogen protects)	↑ risk if unopposed → must add progestogen if uterus intact ^[4]^[13]	This is why combined HRT exists
VTE	↑ (~2× risk, especially in first year)	↑ (less than combined)	Venothrombolic disease (rare in Asians) ^[4]. Risk is primarily with oral route; transdermal carries negligible additional risk
Stroke	Slight ↑ (oral route)	Slight ↑	Risk is small in absolute terms; lower with transdermal route
Coronary heart disease	↑ if started > 10 years after menopause; neutral or ↓ if started < 10 years	↓ if started < 10 years	"Timing hypothesis": oestrogen is cardioprotective if started in the "window of opportunity" (< 60 years old or < 10 years post-menopause) while arteries are still healthy. Starting late, when atherosclerosis is established, may destabilise plaques
Colorectal cancer	↓ (~37% reduction)	Neutral	Unexpected benefit
Dementia	↑ if started > 65; no benefit if started early	Uncertain	Another reason not to start HRT in older women

The Timing Hypothesis — Critical Concept

The WHI initially alarmed everyone because it studied older women (mean age 63) who started HRT many years after menopause. The increased cardiovascular risk applied to this older population. Subsequent re-analyses and the Danish Osteoporosis Prevention Study showed that HRT started within 10 years of menopause (or age < 60) is associated with reduced cardiovascular risk. This is because healthy endothelium responds to oestrogen with ↑ NO and vasodilation, but atherosclerotic arteries respond to oestrogen with inflammation and plaque instability.

Follow-up ^[1]^[3]:

Timepoint	What to Do
1st visit ^[3]	Baseline investigations: confirm menopause (FSH/LH/E2 if clinical features atypical), BP/P, urinalysis, lipid profile, LFT, bone biochemistry, TSH, mammography ^[3]. Choose suitable regimen
2nd visit in 2–4 months ^[3]	Assess patient's acceptance and compliance, symptom control, side effects ^[3]
Subsequent F/U every 6–12 months ^[3]	Routine PE: body weight, BP, urinalysis, general/thyroid/cardiac/chest/abdominal/breast/pelvic exam ^[3]. Routine investigations: cervical smear (Q3y), mammogram ± lipid profile, LFT, fasting glucose (Q2y), BMD if indicated ^[3]
Annual review ^[1]	Annual monitoring for the continual need ^[1] — reassess whether symptoms still warrant HRT

Side effects (usually transient): breast tenderness, fluid retention, bloating, nausea, headache, irregular bleeding ^[1]^[3]

Bleeding pattern monitoring ^[3]:

Breakthrough bleeding in first 6 months of treatment requires no immediate intervention ^[3]
For combined cyclical regimen: if bleeding is not around time of progestin withdrawal or persistently irregular → endometrial biopsy ^[3]
For continuous combined regimen: if bleeding occurs after achievement of amenorrhoea → endometrial biopsy ^[3]
Report unscheduled bleeding promptly if it occurs after 3 months ^[1]

Stopping HRT: no universal rule ^[3]:

Principle = lowest dose for shortest possible duration for symptom relief ^[3]
Exception: POI ^[3] — continue until at least age 51
Cessation: tapering vs abrupt stop (no proven difference in clinical outcome); symptom recurrence ^[1] may occur in ~50% of women

3. Non-Hormonal Treatments

Non-hormonal treatments ^[1] — used when HRT is contraindicated, declined by the patient, or as adjuncts:

Treatment	Mechanism	Evidence / Notes
Clonidine ^[1]	Central α₂-adrenergic agonist → reduces central sympathetic outflow and modulates thermoregulatory centre	Modest efficacy (~1–2 fewer flushes/day vs placebo). Side effects: dry mouth, drowsiness, postural hypotension. Historically one of the first non-hormonal options
Gabapentin ^[1]	Modulates voltage-gated Ca²⁺ channels → unclear exact mechanism for vasomotor relief, possibly stabilises thermoregulatory centre via GABAergic effects	Reduces flushes by ~50%. Side effects: dizziness, somnolence, peripheral oedema. Also helps with sleep
Fezolinetant (NK3 receptor antagonist)	Blocks neurokinin-3 receptors on KNDy neurons in the hypothalamic arcuate nucleus → directly targets the thermoregulatory dysfunction	FDA-approved 2023; reduces flushes by ~60%. The first mechanism-specific non-hormonal treatment. Well-tolerated; monitoring of LFTs recommended (rare hepatotoxicity). Not yet widely available in HK but rapidly entering international formularies
SSRIs / SNRIs (e.g., paroxetine, venlafaxine, escitalopram)	Serotonin modulates thermoregulation; ↑ serotonergic tone may widen thermoneutral zone	Paroxetine (Brisdelle) is FDA-approved specifically for menopausal vasomotor symptoms. ↓ flushes by ~40–65%. Also helpful if concurrent depression/anxiety. Note: paroxetine should be avoided in women on tamoxifen (inhibits CYP2D6 → ↓ active metabolite endoxifen)
Relaxation, lifestyle modifications ^[1]	Stress reduction → ↓ sympathetic activation → ↓ flush frequency. CBT has evidence for reducing the distress caused by flushes more than their frequency	Recommend as adjuncts

Treatment	Details
Psychological counselling / therapy ^[1]	CBT is evidence-based for menopausal mood and anxiety symptoms; addresses the bio-psycho-social component
Antidepressants ^[1]	SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine, duloxetine) for true clinical depression. HRT alone is NOT sufficient for major depressive disorder
HRT	HRT may improve mild depressive symptoms ^[3] — especially when mood disturbance is secondary to sleep disruption from night sweats. Not a primary antidepressant

Treatment	Details
Lubricants ^[1]	Water-based or silicone-based lubricants during intercourse → immediate relief of friction-related dyspareunia. Does not treat underlying atrophy
Moisturisers ^[1]	Applied regularly (2–3×/week) to vaginal mucosa → improve hydration and reduce dryness independent of intercourse. E.g., Replens. Does not treat underlying atrophy
Topical vaginal oestrogen	First-line for urogenital atrophy ^[1]. Restores vaginal epithelial thickness, ↓ pH, restores Lactobacillus, improves vascularity and lubrication. Options: oestriol cream, oestradiol vaginal tablet (Vagifem — 10 μg), oestradiol ring (Estring). Minimal systemic absorption → safe long-term; can be used even in breast cancer survivors (with oncologist agreement for ultra-low-dose preparations)
Ospemifene (oral SERM)	Oestrogenic effect on vaginal epithelium; used for dyspareunia due to GSM. Not widely used in HK

Topical oestrogen for postmenopausal women: ↓ 75% incidence of cystitis in RCTs ^[14] — this is highly effective for reducing recurrent UTIs in postmenopausal women by restoring the vaginal microbiome and urethral mucosal integrity.

4. Management of Osteoporosis in the Menopausal Context

Prevention and treatment of osteoporosis: not based on DXA alone, consider clinical risk factors ^[3]

Patient Profile	Preferred Agent	Rationale
Young, postmenopausal < 65y, no Hx of hip fracture → SERM vs HRT based on symptoms ^[3]	If vasomotor symptoms present → HRT (dual benefit). If asymptomatic → SERM (raloxifene) or bisphosphonate	HRT not indicated for bone alone; SERMs avoid VTE/breast risk differently
Postmenopausal > 65y → bisphosphonate, denosumab ^[3]	Oral bisphosphonate (alendronate 70 mg weekly) first-line; denosumab if intolerant	Hip fracture becomes more important at older age; start late to avoid risks of low bone turnover ^[3]
Severe osteoporosis (T ≤ –3.5, fracture, or ↓ BMD on treatment)	Anabolic agents: teriparatide, romosozumab	Build new bone before switching to anti-resorptive maintenance

4b. Pharmacological Options

Bisphosphonates: e.g., alendronate, risedronate, etidronate, ibandronate ^[3]

The name: "bis-phosphonate" = two phosphonate groups → structurally similar to pyrophosphate (PPi), a natural bone mineral component.

Mechanism ^[4]: Pyrophosphate derivative → binds onto bone surface → "ingested" by osteoclasts → competitive inhibitor of farnesyl pyrophosphate synthase (FPPS) in mevalonate pathway → specific inhibition of bone resorption + induction of osteoclast apoptosis ^[4]

Parameter	Detail
Effect	↓ fracture risk by 50% in both vertebral and non-vertebral fractures (including hip) ^[4]
Route	Oral weekly (alendronate 70 mg, risedronate 35 mg) or IV (zoledronate 5 mg annually, ibandronate 3 mg Q3 months)
Side effects ^[3]	Upper GI upset (most common) → must take on empty stomach with full glass of water and remain upright for ≥ 30 minutes to reduce oesophageal irritation. Atypical femoral fractures (stress fractures of subtrochanteric femur with long-term use > 5 years). Osteonecrosis of the jaw (rare, mainly with IV bisphosphonates and dental procedures) ^[3]
Contraindication ^[3]	Deranged renal function (eGFR < 30–35 mL/min) — bisphosphonates are renally excreted and nephrotoxic at low GFR

SERMs: e.g., raloxifene ^[3]

"SERM" = Selective Estrogen Receptor Modulator — these drugs act as oestrogen agonists in some tissues and antagonists in others.

Parameter	Detail
MoA	Targeted agonist activity in bones without effect on breast/endometrium ^[3]
Bone effect	↓ vertebral but NOT non-vertebral fracture ^[3] — weaker than bisphosphonates
Other effects	↓ risk of breast cancer and endometrial cancer; beneficial effect on lipid profile ^[3]
Indications	NOT for menopausal symptoms (no effect) — asymptomatic women with fear of breast cancer who wish to prevent osteoporosis, especially those with risk factors for breast cancer ^[3]
Key limitation	Little/NO effect on acute menopausal symptoms, may even worsen vasomotor side effects ^[3] — raloxifene can CAUSE hot flushes
Side effects	VTE risk (same as oestrogen HRT), leg cramps, exacerbation of vasomotor symptoms ^[3]

Denosumab (Prolia): "de-" = against, "nosu-" = from "RANKL" (loosely), "-mab" = monoclonal antibody.

Parameter	Detail
MoA	Fully human monoclonal antibody against RANKL → mimics OPG → prevents RANK-RANKL interaction → ↓ osteoclast differentiation, activity, and survival
Route	SC injection 60 mg every 6 months
Effect	↓ vertebral, non-vertebral, and hip fracture risk
Advantages	Can be used if not tolerating bisphosphonate, poor compliance, or CKD ^[4] (no renal dose adjustment needed)
Risks	Rebound vertebral fractures if discontinued abruptly (must transition to bisphosphonate upon cessation); hypocalcaemia (ensure adequate Ca/vit D before starting); ONJ (rare); atypical femoral fracture (rare)

Agent	MoA	Notes
Teriparatide (recombinant PTH 1-34)	Intermittent PTH → preferentially stimulates osteoblasts → ↑ bone formation	SC daily injection × 2 years max. Used for severe osteoporosis. Followed by anti-resorptive to maintain gains
Romosozumab (anti-sclerostin antibody)	Sclerostin (produced by osteocytes) normally inhibits Wnt signalling → inhibits bone formation. Blocking sclerostin → ↑ bone formation AND ↓ bone resorption	SC monthly × 12 months. Dual action. CV safety concern (avoid in recent MI/stroke). Approved 2019 ^[4]

HRT: mainly in early menopause ^[4]

Mechanism: ↓ bone resorption, ↓ urinary Ca excretion, ↓ stromal cell cytokine production → ↓ osteoclastogenesis ^[4]

Additional advantage: ↓ menopausal symptoms ^[4]

Disadvantage: ↑ risk of CA endometrium → must add progestogen if uterus intact; slight ↑ risk of CA breast and CA cervix; venothrombolic disease (rare in Asians) ^[4]

NO longer indicated for osteoporosis ALONE; can be used if vasomotor symptoms ^[4]

Cardiovascular health ^[3]:

Healthy lifestyle: diet, exercise, avoid smoking ^[3]
Control of predisposing factors: e.g., hypertension, DM, lipids, obesity ^[3]

HRT is NOT indicated for primary cardiovascular prevention (despite oestrogen's favourable lipid effects). The timing hypothesis suggests benefit only in the early postmenopausal window, but this is not sufficient evidence to use HRT solely for cardiovascular protection.

Primary ovarian insufficiency (premature menopause) ^[3]:

Principle	Detail
HRT is mandatory, not optional	This is replacement of oestrogen that should physiologically be present — NOT "treatment"
Duration	Continue until at least age 51 (average natural menopause). No extra lifetime risk ^[3] because total oestrogen exposure matches normal women
Regimen	HRT or COCP (young women may prefer the pill for social reasons and contraceptive benefit)
Bone protection	Start early — these women have decades of oestrogen deficiency → high cumulative fracture risk
Fertility	5–10% of POI women have intermittent ovarian function and can spontaneously conceive. Counsel about contraception if pregnancy not desired. Refer to reproductive medicine for fertility options (donor oocyte IVF)
Psychological support	Diagnosis of POI at a young age carries significant emotional impact — grief over lost fertility, premature ageing concerns. Formal psychological support should be offered

Symptom Domain	First-Line	Second-Line / Adjuncts
Vasomotor	Systemic HRT (if no C/I)	Clonidine, gabapentin, SSRIs/SNRIs, fezolinetant, relaxation, lifestyle ^[1]
Urogenital	Topical vaginal oestrogen + lubricants/moisturisers ^[1]	Ospemifene; systemic HRT if systemic symptoms coexist
Psychological	Psychological counselling/therapy; antidepressants ^[1]	HRT for mild mood symptoms secondary to vasomotor Sx ^[3]
Sexual	Treat underlying cause (vaginal oestrogen for dyspareunia; psychosexual counselling for desire issues)	Testosterone (off-label, low-dose transdermal) for persistent ↓ libido unresponsive to oestrogen therapy
Osteoporosis	Lifestyle + Ca/Vit D. Pharmacotherapy if T ≤ –2.5 or high FRAX	HRT if < 65 + symptomatic; bisphosphonate/denosumab if > 65 or C/I to HRT; SERM if breast cancer concern ^[3]
CVD risk	Lifestyle modification, control risk factors	Not HRT for CVD prevention alone

High Yield Summary

HRT Core Rules:

Most effective treatment for vasomotor symptoms; improves QoL ^[1]
Lowest dose for shortest possible duration ^[3] (exception: POI → until age 51)
Uterus present → must add progestogen (otherwise → endometrial cancer risk)
No uterus → oestrogen only
< 2y post-menopause → sequential combined (withdrawal bleed)
> 2y post-menopause → continuous combined (aim for amenorrhoea)
Transdermal route → preferred if ↑ VTE risk (avoids first-pass hepatic effect)

Contraindications to HRT ^[1]: severe liver disease, cerebrovascular disease, DVT/PE, oestrogen-dependent tumours (breast, uterus), undiagnosed uterine bleeding

Non-hormonal options ^[1]: clonidine, gabapentin, relaxation, lifestyle for vasomotor; psychological counselling, antidepressants for mood; lubricants, moisturisers for vaginal atrophy

Osteoporosis management ^[3]:

Young symptomatic → HRT (dual benefit)
Asymptomatic with breast cancer concern → SERM (raloxifene)
Older (> 65) → bisphosphonate or denosumab
Severe → anabolic agent (teriparatide, romosozumab)

POI → HRT is mandatory replacement, not optional treatment; continue until at least age 51

Active Recall - Management of Climacteric Symptoms and Menopause

References

^[1] Lecture slides: Block C - Climacteric symptoms_ menopause and related illness; amenorrhoea.pdf (p23, p27) ^[2] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (p3) ^[3] Senior notes: Adrian Lui Gynecology Notes.pdf (p31–33, p36, p38) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p50–51) ^[12] Senior notes: Maksim Medicine Notes.pdf (p109) ^[13] Senior notes: Ryan Ho Endocrine.pdf (p113) ^[14] Senior notes: Ryan Ho Urogenital.pdf (p126)

Complications of Menopause and Climacteric

Complications of menopause can be thought of in two distinct categories:

Complications of menopause itself — i.e., the long-term consequences of chronic oestrogen deficiency that develop over years to decades if left unaddressed.
Complications of menopause treatment (HRT) — iatrogenic complications from the therapy we use to manage the condition.

Both are examinable, and both require you to understand the "why" — connecting back to oestrogen's physiological roles and the pharmacology of HRT.

A. Complications of Menopause (Chronic Oestrogen Deficiency)

These are the longer-term health conditions ^[1] that develop as a consequence of sustained oestrogen deficiency. They are NOT merely "symptoms" — they are organ-level pathological processes with measurable morbidity and mortality.

Postmenopausal osteoporosis: oestrogen deficiency leads to bone loss. Postmenopausal osteoporosis as an important risk factor for fracture ^[1]^[2]

Why does this happen? (from first principles — detailed in Part 1 but critical to revisit)

Oestrogen is the master regulator of bone remodelling homeostasis. Without it:

↑ RANKL expression by osteoblasts → ↑ osteoclast differentiation and survival
↓ OPG → loss of the competitive decoy receptor that normally neutralises RANKL
↑ number of active remodelling units → more resorption pits
↓ osteoclast apoptosis → osteoclasts live longer and resorb more bone
Net result: bone resorption >> bone formation → progressive loss of BMD

Timeline of bone loss:

Most rapid in the first 5–7 years after menopause: up to 3–5% trabecular bone loss per year
Slows to ~1%/year thereafter (but continues indefinitely)
Trabecular bone (vertebral bodies, distal radius) is disproportionately affected early → vertebral fractures are the earliest clinical manifestation

The three classic fragility fracture sites ^[4]:

Fracture Site	Mechanism	Clinical Consequence
Vertebral compression fracture ^[4]	Trabecular bone loss in vertebral bodies → axial load exceeds bone strength → wedge/crush fracture	Acute mechanical low back pain ± radiation, height loss, thoracic kyphosis ("dowager's hump") ^[4]. May be asymptomatic (incidental finding on CXR). Multiple fractures → progressive loss of height (up to 20 cm), restrictive lung disease from kyphosis, chronic pain, loss of independence
Hip fracture ^[4]	Fall from standing height landing on hip → fracture of femoral neck or intertrochanteric region	Most devastating: 20–30% one-year mortality in elderly; 50% lose independent mobility; high surgical morbidity. Incidence rises exponentially after 70
Distal forearm (Colles') fracture ^[4]	Fall on outstretched hand (FOOSH) → fracture of distal radius ± ulna	Earliest fracture type to present (typically in late 50s–60s); "dinner fork" deformity; usually good functional recovery but signals underlying osteoporosis

Hong Kong prevalence ^[4]: 60–69y: 1:6; 70–79y: 1:5; ≥ 80y: 1:4

The Fracture Cascade

One fragility fracture dramatically increases the risk of subsequent fractures. A single vertebral fracture → 5× risk of another vertebral fracture and 2–3× risk of hip fracture. This is the "fracture cascade" — identifying and treating the first fracture is critical to prevent the domino effect.

Diagnosis: DEXA scan — T-score ≤ –2.5 = osteoporosis; T-score ≤ –2.5 + fragility fracture = severe (established) osteoporosis ^[12]

Management: see Management section — lifestyle, Ca/Vit D, bisphosphonates, denosumab, teriparatide, HRT if symptomatic ^[3]^[4]

Cardiovascular disease: incidence increases after menopause. Oestrogen probably protective to vasculature and has favourable effect on lipid profile ^[1]

This is arguably the most important complication in terms of population-level mortality. Cardiovascular disease (IHD + stroke) is the leading cause of death in postmenopausal women — more than breast cancer, more than any other malignancy.

Why does cardiovascular risk rise after menopause? Oestrogen exerts multiple cardioprotective effects that are lost after menopause:

Protective Effect of Oestrogen	What Happens When Oestrogen Is Lost
Lipid profile: ↑ HDL (↑ hepatic apoA-I, ↓ hepatic lipase), ↓ LDL (↑ hepatic LDL receptor), ↓ Lp(a)	Atherogenic dyslipidaemia: ↑ LDL, ↑ total cholesterol, ↓ HDL, ↑ triglycerides
Endothelial function: ↑ endothelial NO synthase (eNOS) → ↑ NO → vasodilation, anti-platelet, anti-inflammatory	Endothelial dysfunction: ↓ NO-mediated vasodilation → ↑ vascular tone, ↑ inflammation, ↑ oxidative stress → accelerated atherogenesis
Insulin sensitivity: oestrogen enhances insulin signalling in skeletal muscle and liver	Insulin resistance → metabolic syndrome → ↑ risk of type 2 diabetes
Body fat distribution: oestrogen promotes gluteofemoral (subcutaneous) fat deposition	Central (visceral) adiposity → ↑ visceral fat → ↑ inflammatory cytokines (IL-6, TNF-α) → ↑ cardiometabolic risk
Vascular smooth muscle: oestrogen inhibits smooth muscle proliferation and migration	Vascular remodelling → contributes to arterial stiffness and hypertension
Coagulation: complex but net anti-thrombotic effect in physiological concentrations	Prothrombotic shift (though this is complex — oral HRT can paradoxically increase thrombotic risk)

Clinical consequences:

Coronary artery disease (CAD): incidence in women rises sharply after menopause to match or exceed male rates by age 70
Stroke: ischaemic stroke risk increases
Peripheral arterial disease: claudication, critical limb ischaemia
Hypertension: BP rises modestly after menopause (loss of oestrogen-mediated vasodilation + weight gain + insulin resistance)

Prevention ^[3]: Healthy lifestyle: diet, exercise, avoid smoking. Control of predisposing factors: e.g., HT, DM, lipids, obesity ^[3]. HRT is NOT recommended for primary CVD prevention (despite the biological rationale), based on current evidence.

Urogenital atrophy ^[1]^[2]:

Vaginal	Urinary
Dryness	Urgency
Burning	Frequency
Pruritus	Dysuria
Dyspareunia	Urinary tract infection
Prolapse	Incontinence
	Voiding difficulties

Unlike vasomotor symptoms (which tend to self-limit over years), GSM is progressive and does NOT resolve without treatment. It affects up to 50% of postmenopausal women and significantly impairs quality of life.

Why is it progressive? The vagina, urethra, bladder trigone, and pelvic floor are oestrogen-dependent tissues (rich in ERα and ERβ). Without oestrogen, they undergo continuous atrophy — there is no adaptive mechanism:

Pathological Change	Clinical Consequence
Vaginal epithelial thinning (loss of stratified squamous layers) → loss of glycogen stores	↓ Lactobacillus colonisation → ↑ vaginal pH (from 3.5–4.5 to > 5.0) → loss of protective acid mantle → ↑ susceptibility to pathogenic bacteria and candida
↓ vaginal blood supply	↓ transudate lubrication → dryness, burning
Loss of collagen and elastic fibres in vaginal wall	↓ elasticity, narrowing of introitus, loss of rugae → dyspareunia, petechiae on examination
Urethral mucosal atrophy	↓ urethral closure pressure → stress urinary incontinence; ↓ barrier to bacterial adhesion → recurrent UTIs
Detrusor changes	Overactive bladder → urgency, frequency
Pelvic floor collagen loss	Pelvic organ prolapse (cystocele, rectocele, uterine descent) — compounded by prior obstetric injury

Recurrent UTIs: a particularly important complication. Topical oestrogen for postmenopausal women: ↓ 75% incidence of cystitis in RCTs ^[14] — this is one of the most evidence-based applications of topical vaginal oestrogen.

Management: topical vaginal oestrogen is first-line; lubricants and moisturisers as adjuncts ^[1].

Psychological symptoms: loss of energy and drive, loss of concentration, irritability, anxiety, depression, mood fluctuations, sleep disturbances ^[1]^[2]

Can be multifactorial: Bio-psycho-social factors! ^[1]^[2]

While these are primarily "symptoms" of the climacteric, they can become persistent complications when they evolve into established psychiatric conditions:

Complication	Mechanism	Clinical Significance
Major depressive disorder	Oestrogen withdrawal → ↓ serotonergic tone; compounded by sleep disruption, psychosocial stressors (empty nest, ageing, caregiving burden). Perimenopausal women have 2–4× risk of first-episode depression	May require antidepressant treatment; HRT alone is insufficient for true MDD
Chronic insomnia	Night sweats disrupt sleep architecture; ↓ progesterone (GABAergic sedative) and oestrogen (REM-promoting) → fragmented sleep	If persistent, leads to daytime fatigue, impaired concentration, ↑ accident risk, ↑ CVD risk
Anxiety disorders	Fluctuating oestrogen destabilises noradrenergic system; psychosocial vulnerabilities amplified	May meet criteria for GAD or panic disorder; distinguish from vasomotor-related palpitations
Cognitive decline	Oestrogen has neurotrophic effects on hippocampal cholinergic neurons (via BDNF). Epidemiological data suggest association between early menopause/POI and increased dementia risk	Controversial: WHI showed HRT started > 65 years may INCREASE dementia risk; early HRT (< 60 years) may be neutral or protective. The "critical window hypothesis" for cognition remains unproven

Sexual dysfunction: dyspareunia — atrophic change; decreased libido. Can be multifactorial ^[1]^[2]

This is a complication that significantly impacts quality of life and relationships:

Component	Mechanism
Dyspareunia	Vaginal atrophy → thin, dry, inelastic mucosa → friction → pain → avoidance → further disuse atrophy (vicious cycle)
Decreased libido	↓ Ovarian testosterone + ↓ oestradiol + dyspareunia-related avoidance + mood disturbance + altered body image
Arousal difficulty	↓ Genital vasocongestion (oestrogen-dependent clitoral and vulvar blood flow) + ↓ nerve sensitivity
Anorgasmia	↓ Pelvic nerve sensitivity + psychological factors

Management: vaginal oestrogen for dyspareunia; psychosexual counselling; consider low-dose transdermal testosterone for persistent ↓ libido unresponsive to oestrogen (off-label but evidence-supported by the Global Consensus Position Statement on Testosterone Therapy for Women, 2019).

Complication	Mechanism
Skin thinning and ageing	Oestrogen maintains dermal collagen (types I and III) and hyaluronic acid. Postmenopause: ~2% collagen loss per year for the first 5 years → thin, dry, wrinkled, easily bruised skin
Hair changes	Relative androgen excess (adrenal androgens unopposed by ↓ oestrogen) → thinning of scalp hair (androgenic alopecia pattern) + ↑ facial hair (upper lip, chin)
Arthralgia	Oestrogen has anti-inflammatory and chondroprotective effects on synovium and cartilage. Withdrawal → ↑ joint stiffness, pain. May accelerate osteoarthritis progression
Sarcopenia	↓ Oestrogen + ↓ testosterone + ageing → ↓ muscle protein synthesis, ↓ satellite cell activation → loss of lean muscle mass → weakness, ↑ fall risk → compounds fracture risk

During the perimenopause, anovulatory cycles produce unopposed oestrogen (no progesterone from a corpus luteum) → endometrial proliferation without secretory transformation → irregular, sometimes heavy bleeding.

If this persists, it creates a risk of:

Endometrial hyperplasia (simple → complex → atypical) → precursor to endometrial adenocarcinoma
Endometrial carcinoma — especially in obese women (↑ peripheral aromatisation of adrenal androgens to oestrone → chronic unopposed oestrogenic stimulation)

Postmenopausal Bleeding

Any bleeding occurring ≥ 12 months after the final menstrual period is postmenopausal bleeding (PMB) and is endometrial cancer until proven otherwise. It demands investigation: transvaginal USS (endometrial thickness) → endometrial biopsy/hysteroscopy if endometrium > 4 mm or clinical suspicion.

B. Complications of Menopause Treatment (HRT)

These are iatrogenic complications — the price paid for symptom relief. Understanding them is essential for informed consent and for the exam.

Parameter	Detail
Risk	~2× baseline risk with oral combined HRT, especially in the first year
Mechanism	Oral oestrogen undergoes first-pass hepatic metabolism → ↑ hepatic synthesis of clotting factors (Factor VII, X, fibrinogen) + ↓ antithrombin III + ↑ activated protein C resistance
Mitigator	Transdermal oestrogen bypasses liver → negligible additional VTE risk. Venothrombolic disease (rare in Asians) ^[4] — the absolute risk in Asian populations is lower than in Caucasians because the baseline incidence of VTE is lower
Clinical significance	DVT → PE (potentially fatal). Screen for personal/family history of VTE, thrombophilia before starting HRT. Prefer transdermal route in high-risk women

Slight ↑ risk of CA breast ^[4]

Parameter	Detail
Risk	Combined HRT (oestrogen + progestogen): RR ~1.26 after > 5 years of use. Translates to ~8 additional cases per 10,000 women per year. Risk returns to baseline ~5 years after stopping
Mechanism	Progestogen (especially synthetic MPA) promotes breast epithelial cell proliferation, inhibits apoptosis, and may enhance oestrogen receptor signalling in breast tissue. Oestrogen alone (without progestogen) does NOT increase — and may slightly decrease — breast cancer risk (WHI oestrogen-only arm)
Clinical significance	The risk is attributable primarily to the progestogen component. Micronised progesterone may carry lower risk than synthetic progestogens (observational data). Risk is comparable to other common risk factors: late menopause (> 55), obesity, alcohol use
Risk factor context	HRT (effect disappears after 5 years of stopping) ^[15]. Late menopause (> 55y) and oestrogen-based OCP also contribute to total lifetime oestrogen exposure and breast cancer risk ^[15]
Screening	Mammography before starting HRT and regular screening throughout use

Perspective on Breast Cancer Risk

The HRT breast cancer risk is often overemphasised relative to its magnitude. The additional risk is similar to that conferred by drinking 2 glasses of wine daily or being obese. It is important for informed consent but should not be used to blanket-deny HRT to symptomatic women. Individualise the decision.

↑ risk of CA endometrium → must add progestogen if uterus intact ^[4]^[13]

Parameter	Detail
Risk	Unopposed oestrogen: 2–10× increased risk of endometrial cancer depending on duration (with > 10 years of use, risk is ~10×)
Mechanism	Oestrogen drives endometrial proliferation. Without progesterone to induce secretory transformation and shedding, the endometrium undergoes hyperplasia (simple → complex → atypical → carcinoma) — the hyperplasia-to-carcinoma sequence
Prevention	Adding progestogen for ≥ 12–14 days per cycle (sequential) or continuously eliminates the excess risk → this is why combined HRT exists. LNG-IUS (Mirena) provides highly effective local endometrial protection
Monitoring	Report any unscheduled bleeding → endometrial biopsy if bleeding pattern is abnormal ^[3]

Parameter	Detail
Risk	Slight increase (~1.3×) with oral HRT, mainly ischaemic stroke
Mechanism	Oral oestrogen → ↑ prothrombotic factors; also may have complex effects on cerebral vasculature. Transdermal route appears to have lower or no additional stroke risk
Clinical significance	Risk is small in absolute terms in younger, healthy women. Avoid HRT in women with active cerebrovascular disease (cerebral vascular disease is a contraindication ^[1])

Parameter	Detail
Risk	↑ risk of gallstones and cholecystitis with oral HRT
Mechanism	Oral oestrogen → ↑ hepatic cholesterol secretion into bile → ↑ cholesterol saturation → lithogenic bile → gallstone formation
Mitigator	Transdermal route avoids first-pass hepatic effect → lower gallstone risk

Parameter	Detail
Risk	Some observational studies suggest a small ↑ risk with prolonged HRT use (> 5–10 years), mainly serous histology
Magnitude	Very small: ~1 additional case per 1,000 women over 5 years of use
Clinical significance	Not a strong enough signal to be a primary concern in HRT decision-making, but included in comprehensive counselling

C. Complications of Osteoporosis Treatment

Since osteoporosis management is a core part of menopause care, complications of anti-resorptive therapy deserve mention:

Complication	Mechanism	Clinical Detail
Upper GI upset (most common) ^[3]^[12]	Direct mucosal irritation of oesophageal and gastric epithelium by bisphosphonate tablet	Take on empty stomach, remain upright ≥ 30 min ^[3]^[12]. Can cause oesophagitis, oesophageal ulceration. Avoid in patients with oesophageal stricture or achalasia
Atypical femoral fracture ^[3]^[12]	Prolonged suppression of bone remodelling → inability to repair microdamage in cortical bone → stress fracture of subtrochanteric/diaphyseal femur	Occurs with long-term use (> 5 years). Presents with prodromal thigh pain. Reason for drug holidays — reassess at 3–5 years
Osteonecrosis of the jaw (ONJ) ^[3]^[12]	Bisphosphonate concentrates in jaw bone (high turnover); suppresses remodelling → avascular necrosis after dental procedures	Rare, potentially serious ^[3]. Dental assessment before starting. More common with IV bisphosphonates and in oncology doses (zoledronate for bone metastases)
Hypocalcaemia ^[12]	Rapid suppression of osteoclastic resorption → ↓ Ca²⁺ release from bone → may cause symptomatic hypocalcaemia if Ca/Vit D intake inadequate	Always ensure adequate Ca/Vit D supplementation before starting. At least 4 weeks of Ca/vitamin D supplement beforehand for IV zoledronate ^[12]
Renal toxicity ^[12]	Bisphosphonates are renally excreted; nephrotoxic at high concentrations	C/I in renal failure ^[3]^[12] (eGFR < 30–35). Use denosumab instead if eGFR low
Flu-like symptoms ^[12]	Acute-phase reaction (release of IL-6, TNF-α from monocytes)	IV only ^[12]. First dose worst; self-limiting within 72 hours. Treat with paracetamol

Complication	Mechanism
Rebound vertebral fractures on discontinuation	Denosumab blocks RANKL → when withdrawn, RANKL surges → massive osteoclast activation → rapid bone loss → multiple vertebral fractures can occur within months. Must transition to bisphosphonate before stopping
Hypocalcaemia	Same mechanism as bisphosphonates — ensure Ca/Vit D adequacy
ONJ and atypical fracture	Same mechanism as bisphosphonates but lower incidence

Complication	Mechanism
VTE risk (same as oestrogen HRT) ^[3]	Raloxifene, like oestrogen, has pro-thrombotic effects through hepatic pathways
Exacerbation of vasomotor symptoms ^[3]	Acts as oestrogen antagonist in the hypothalamus → may worsen thermoregulatory dysfunction → more hot flushes
Leg cramps ^[3]	Mechanism uncertain; possibly related to effects on calcium handling in skeletal muscle

POI deserves special mention because the complications are more severe and cumulative due to the longer duration of oestrogen deficiency:

Complication	Why Worse in POI
Osteoporosis	Decades of oestrogen deprivation → much greater cumulative bone loss than natural menopause. DEXA mandatory. HRT essential until age 51
Cardiovascular disease	Earlier onset of atherogenic lipid profile, endothelial dysfunction, insulin resistance. Studies show ↑ CVD mortality in women with menopause < 40 vs. natural age
Infertility	Most impactful personal consequence. 5–10% have intermittent ovarian function, but spontaneous conception is rare. Donor oocyte IVF is the primary fertility option
Psychological morbidity	Grief over lost fertility, premature ageing, identity disruption. ↑ rates of depression and anxiety. Formal psychological support should be offered
Cognitive concerns	Observational data suggest early menopause is associated with ↑ risk of later cognitive decline/dementia — further reason to replace oestrogen early
Autoimmune comorbidities	Autoimmune POI frequently coexists with autoimmune thyroiditis (Hashimoto's), Addison disease, T1DM as part of autoimmune polyendocrine syndrome → screen for these

Category	Complication	Primary Mechanism	Key Clinical Point
Oestrogen deficiency	Osteoporosis and fractures ^[1]	↑ RANKL:OPG → ↑ osteoclast activity	Most rapid bone loss in first 5–7 years; vertebral > hip > wrist
	Cardiovascular disease ^[1]	Loss of endothelial NO, atherogenic lipids, insulin resistance	#1 killer in postmenopausal women
	Urogenital atrophy (GSM) ^[1]^[2]	Atrophy of oestrogen-dependent urogenital epithelium	Progressive; does NOT self-resolve; topical oestrogen effective
	Recurrent UTI	↑ Vaginal pH, ↓ Lactobacillus, urethral atrophy	Topical oestrogen ↓ 75% cystitis incidence ^[14]
	Depression / anxiety	↓ Serotonin + psychosocial factors	Bio-psycho-social ^[1]; distinguish from true MDD
	Sexual dysfunction	Vaginal atrophy + ↓ testosterone + psychological	Multifactorial; vaginal oestrogen + psychosexual Rx
	Endometrial pathology	Anovulatory perimenopausal cycles → unopposed oestrogen	PMB = investigate for endometrial cancer
HRT-related	VTE	Oral oestrogen ↑ hepatic clotting factors	Use transdermal to mitigate; rare in Asians ^[4]
	Breast cancer ^[4]	Progestogen promotes breast epithelial proliferation	Risk mainly from combined HRT > 5 years; returns to baseline after stopping
	Endometrial cancer ^[4]	Unopposed oestrogen → hyperplasia → carcinoma	Add progestogen if uterus present
	Stroke	Prothrombotic + vascular effects	C/I in active cerebrovascular disease ^[1]
	Gallstones	Oral oestrogen ↑ biliary cholesterol saturation	Use transdermal to mitigate
Anti-resorptive Rx	Atypical femoral fracture ^[3]^[12]	Suppressed remodelling → unrepaired cortical microdamage	Drug holiday after 3–5 years
	Osteonecrosis of jaw ^[3]^[12]	Jaw bone remodelling suppression → avascular necrosis	Dental check before starting
	Rebound fractures (denosumab)	RANKL surge on discontinuation	Must bridge to bisphosphonate

High Yield Summary

The Big Three Complications of Menopause (always mention in SAQs):

Postmenopausal osteoporosis → fragility fractures (vertebral, hip, wrist). Most rapid bone loss in first 5–7 years. Treat with HRT/bisphosphonates/denosumab ^[1]
Cardiovascular disease → #1 cause of death in postmenopausal women. Driven by atherogenic lipid profile, endothelial dysfunction, insulin resistance, central adiposity ^[1]
Genitourinary syndrome of menopause (GSM) → progressive and does NOT self-resolve. Topical oestrogen is first-line ^[1]^[2]

Complications of HRT (always mention in counselling questions):

VTE (oral > transdermal), breast cancer (combined > oestrogen-only; progestogen-driven), endometrial cancer (only with unopposed oestrogen), stroke, gallstones
Venothrombolic disease rare in Asians ^[4]
HRT breast cancer effect disappears after 5 years of stopping ^[15]

Complications of osteoporosis Rx:

Bisphosphonates: GI upset, atypical femoral fracture, ONJ, hypocalcaemia, renal toxicity
Denosumab: rebound vertebral fractures on discontinuation (must bridge to bisphosphonate)

POI-specific: all complications are worse and more cumulative → HRT is mandatory replacement until age 51

Active Recall - Complications of Menopause and Its Treatment

References

^[1] Lecture slides: Block C - Climacteric symptoms_ menopause and related illness; amenorrhoea.pdf (p18–19, p22) ^[2] Lecture slides: GC 114. Climacteric symptoms menopause and related illness; amenorrhoea.pdf (p38–39, p41) ^[3] Senior notes: Adrian Lui Gynecology Notes.pdf (p32–33, p38) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p51, p110) ^[12] Senior notes: Maksim Medicine Notes.pdf (p109–110) ^[13] Senior notes: Ryan Ho Endocrine.pdf (p113) ^[14] Senior notes: Ryan Ho Urogenital.pdf (p126) ^[15] Senior notes: Ryan Ho Fundamentals.pdf (p371)

High Yield Summary

Definitions:

Climacteric = years of waning ovarian function (transitional era)
Menopause = permanent cessation of ovarian function; 12 months amenorrhoea (retrospective clinical diagnosis)
Perimenopause = first signs of approaching menopause → 12 months after FMP
POI = menopause < age 40 (pathological; FSH > 25 on 2 occasions ≥ 4 weeks apart)

Pathophysiology: Follicular depletion → ↓inhibin B → ↑FSH (earliest change) → ↓oestradiol → hypergonadotropic hypogonadism. Perimenopause may have erratic high E2 before permanent fall.

Postmenopausal hormones: ↑↑ FSH, ↑ LH, ↓↓ E2, undetectable AMH. Oestrone (E1) from peripheral aromatisation in adipose tissue.

Four pillars of symptoms:

Vasomotor (hot flushes, sweats, palpitations) — narrowed thermoneutral zone via KNDy neurons (NK3 pathway; fezolinetant)
Psychological (mood, insomnia, poor concentration) — bio-psycho-social; ↓serotonin
Urogenital (GSM) — progressive, does NOT self-resolve
Sexual (dyspareunia, ↓libido) — multifactorial

Long-term consequences: Osteoporosis (↑RANKL:OPG → trabecular bone loss, most rapid first 5–7 years), CVD (#1 killer postmenopause — loss of endothelial NO, atherogenic lipids).

Vasomotor symptoms: Median duration 7.4 years; 75–80% of women affected.

High Yield Summary — Differential Diagnosis

Exam-tested differentials: Thyrotoxicosis and anxiety/panic disorder.

Climacteric feature	Key mimics	Discriminator
Hot flushes	Thyrotoxicosis, phaeochromocytoma, carcinoid, panic disorder, drugs	Thyrotoxicosis = constant hypermetabolism (weight loss, diarrhoea, warm moist skin); menopause = episodic 2–4 min flushes. Phaeochromocytoma = pallor (not flushing), severe HTN
Amenorrhoea	Pregnancy, hypothalamic amenorrhoea, PCOS, hyperprolactinaemia, thyroid, POI, Asherman	Always β-hCG first at any age
Mood disturbance	MDD, GAD, adjustment disorder, hypothyroidism, OSA	HRT helps mild mood secondary to vasomotor; true MDD needs antidepressants
Vaginal dryness	Candidiasis, BV, lichen sclerosus, malignancy	GSM: pH > 5, pale thin mucosa, responds to topical oestrogen

Thyrotoxicosis vs menopause: Constant heat intolerance vs episodic flushes; weight loss vs central adiposity; persistent tachycardia vs episodic; TFTs (TSH ↓, fT4 ↑).

↑FSH should NOT diagnose menopause in women ≥ 45 with classic presentation — it rises years before menopause and fluctuates.

POI vs natural menopause: Age < 40; requires karyotype, FMR1, autoimmune screen, mandatory early DEXA and essential HRT.

High Yield Summary — Diagnosis

Menopause is a clinical, retrospective diagnosis — ≥ 12 months amenorrhoea in woman of appropriate age with no other cause.

Scenario	FSH needed?
Age ≥ 45, typical symptoms + 12 months amenorrhoea	No — clinical diagnosis
Age 40–44	Consider FSH (× 2, ≥ 4–6 weeks apart)
Age < 40 (POI)	Yes — FSH > 25 × 2, ≥ 4 weeks apart + full workup
Post-hysterectomy (ovaries retained)	Consider FSH
On hormonal contraception	Cannot rely on FSH

POI workup: Karyotype, FMR1, anti-adrenal/TPO antibodies, DEXA, pelvic USS.

Mandatory differentials: β-hCG, TFTs, FSH/LH/E2, prolactin.

DEXA: T-score ≥ –1.0 normal | –1.0 to –2.5 osteopenia | ≤ –2.5 osteoporosis. Z-score ≤ –2.0 in premenopausal → suspect secondary cause.

PMB rule: Any bleeding ≥ 12 months post-FMP → investigate for endometrial cancer (TVUS ± biopsy).

Symptom tools: MRS, Greene Climacteric Scale, PHQ-9/GAD-7 for psychological screening.

Pre-HRT baseline: Mammogram, BP, lipid profile, cervical screening status.

High Yield Summary — Management

Principles: Holistic bio-psycho-social approach; most women need no active treatment; treat bothersome symptoms; prevent long-term consequences.

Lifestyle (all women): Exercise, smoking cessation, healthy diet, Ca 1200 mg + Vit D 800–1000 IU/day, avoid alcohol/spicy food, layered clothing, stress reduction.

HRT — most effective for vasomotor symptoms:

Scenario	Regimen
Uterus present, < 2y post-menopause	Sequential combined (oestrogen + cyclical progestogen)
Uterus present, > 2y post-menopause	Continuous combined (aim amenorrhoea)
No uterus	Oestrogen-only
Isolated urogenital symptoms	Topical vaginal oestrogen (no progestogen needed)

Route: Transdermal preferred if ↑VTE risk (avoids first-pass hepatic ↑clotting factors). Oral ↑VTE, gallstones.

Contraindications ^[1]: Severe liver disease, cerebrovascular disease, DVT/PE, oestrogen-dependent tumours, undiagnosed uterine bleeding.

Timing hypothesis: Start within 10 years of menopause or age < 60 for best risk:benefit.

POI: HRT is mandatory replacement until at least age 51 — not optional.

Non-hormonal vasomotor: Fezolinetant (NK3 antagonist), gabapentin, clonidine, SSRIs/SNRIs, CBT.

Osteoporosis: Young symptomatic → HRT (dual benefit). Asymptomatic + breast concern → raloxifene. Older (> 65) → bisphosphonate/denosumab. Severe → teriparatide/romosozumab.

Follow-up: 2nd visit 2–4 months; then 6–12 monthly. Bleeding after amenorrhoea on continuous combined → endometrial biopsy.

High Yield Summary — Complications

The Big Three of untreated menopause:

Osteoporosis → fragility fractures (vertebral, hip, wrist). HK prevalence: 60–69y 1:6; ≥80y 1:4. Most rapid loss first 5–7 years.
Cardiovascular disease — #1 cause of death postmenopause (↑LDL, ↓HDL, endothelial dysfunction, insulin resistance, central adiposity).
GSM — progressive vaginal/urinary atrophy; topical oestrogen ↓UTI incidence 75% in RCTs.

Psychological: 2–4× ↑depression risk in perimenopause; chronic insomnia; cognitive complaints (HRT not proven to prevent dementia if started late).

Sexual dysfunction: Dyspareunia (atrophy), ↓libido (↓ovarian testosterone + psychological).

Perimenopausal AUB: Unopposed oestrogen → endometrial hyperplasia → carcinoma. PMB = investigate.

HRT complications: VTE (oral > transdermal), breast cancer (combined > 5 years, mainly progestogen-driven; returns to baseline ~5 years after stopping), endometrial CA (unopposed oestrogen only), stroke, gallstones.

Anti-resorptive Rx: Bisphosphonates — GI upset, atypical femoral fracture, ONJ. Denosumab — rebound vertebral fractures on stopping (must bridge to bisphosphonate). Raloxifene — VTE, worsens vasomotor symptoms.

POI-specific: Greater cumulative bone/CVD risk, infertility grief, autoimmune comorbidities — HRT essential until age 51.

Climacteric Symptoms And Menopause

References

Climacteric Symptoms and Menopause

2. Epidemiology

4. Anatomy and Physiology — The Hypothalamic-Pituitary-Ovarian (HPO) Axis

5. Etiology and Pathophysiology of Menopause

Pathophysiology of Specific Climacteric Symptoms

The STRAW+10 Staging System (Stages of Reproductive Ageing Workshop)

7. Clinical Features — Symptoms and Signs

7a. Symptoms

Premature Ovarian Insufficiency (POI) — A Special Category

Active Recall - Climacteric Symptoms and Menopause

Differential Diagnosis of Climacteric Symptoms

1. Differential Diagnosis of Vasomotor Symptoms

Active Recall - Differential Diagnosis of Climacteric Symptoms

References

Diagnostic Criteria, Algorithm and Investigations for Climacteric Symptoms and Menopause

1. Diagnostic Criteria

3. Investigation Modalities — Detailed Interpretation

3a. First-Line Investigations (for all women presenting with suspected menopause)

3b. Second-Line Investigations — For Specific Clinical Scenarios

Active Recall - Diagnosis and Investigations of Menopause

References

Management of Climacteric Symptoms and Menopause

2. Hormone Replacement Therapy (HRT) — The Cornerstone

2d. Routes of Administration

3. Non-Hormonal Treatments

4. Management of Osteoporosis in the Menopausal Context

4b. Pharmacological Options

Active Recall - Management of Climacteric Symptoms and Menopause

References

Complications of Menopause and Climacteric

A. Complications of Menopause (Chronic Oestrogen Deficiency)

B. Complications of Menopause Treatment (HRT)

C. Complications of Osteoporosis Treatment

Active Recall - Complications of Menopause and Its Treatment

References

On this page

Climacteric Symptoms And Menopause

1. Definition and Terminology

2. Epidemiology

Age of Onset

Prevalence of Symptoms

Hong Kong-Specific Points

3. Risk Factors for Earlier Menopause

4. Anatomy and Physiology — The Hypothalamic-Pituitary-Ovarian (HPO) Axis

The Normal Menstrual Cycle (Recap)

Key Ovarian Hormones and Their Target Actions

Follicular Dynamics and Ageing

5. Etiology and Pathophysiology of Menopause

Why Does Menopause Happen? (First Principles)

Types of Menopause by Etiology

Pathophysiology of Specific Climacteric Symptoms

5a. Vasomotor Symptoms (Hot Flushes, Night Sweats)

5b. Psychological Symptoms

5c. Sexual Dysfunction

5d. Urogenital Atrophy (Genitourinary Syndrome of Menopause — GSM)

5e. Longer-Term Health Conditions

5f. Other Longer-Term Effects

6. Classification / Staging

7. Clinical Features — Symptoms and Signs

7a. Symptoms

Acute/Subacute (Perimenopausal and Early Postmenopausal)

Intermediate (Months to Years Postmenopause)

Late/Long-Term (Years to Decades Postmenopause)

7b. Signs

8. Additional Relevant Associations

Active Recall - Climacteric Symptoms and Menopause

References

Why a Differential Diagnosis Matters

Organising Framework

1. Differential Diagnosis of Vasomotor Symptoms

a. Thyrotoxicosis [3]

b. Phaeochromocytoma

c. Carcinoid Syndrome

d. Systemic Mastocytosis

e. Panic Disorder / Anxiety Disorders

f. Drug-Induced Flushing

2. Differential Diagnosis of Amenorrhoea in the Perimenopausal Age Group

3. Differential Diagnosis of Psychological Symptoms

4. Differential Diagnosis of Urogenital Symptoms

5. Differential Diagnosis Summary Table — Organised by Mimicked Feature

Clinical Approach to Differentiating — A Practical Algorithm

Special Consideration: Premature Ovarian Insufficiency (POI) vs. Natural Menopause

Active Recall - Differential Diagnosis of Climacteric Symptoms

Overarching Principle: Menopause is a Clinical Diagnosis

1. Diagnostic Criteria

1a. Natural Menopause

1b. Premature Ovarian Insufficiency (POI)

1c. Perimenopause

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Interpretation

3a. First-Line Investigations (for all women presenting with suspected menopause)

i. β-hCG (Urine or Serum)

ii. Thyroid Function Tests (TFTs)

iii. Gonadotrophins — FSH and LH

iv. Oestradiol (E2)

v. Prolactin

3b. Second-Line Investigations — For Specific Clinical Scenarios

vi. Pelvic Ultrasound (Transvaginal USS)

vii. Endometrial Biopsy / Hysteroscopy

viii. DEXA Scan (Dual-Energy X-ray Absorptiometry)

ix. Cardiovascular Risk Assessment

3c. Third-Line Investigations — For POI Workup

3d. Other Investigations in Specific Contexts

4. Symptom Severity Assessment Tools

5. Putting It All Together — Investigation Checklist by Clinical Scenario

Active Recall - Diagnosis and Investigations of Menopause

Overarching Management Principles

Management Algorithm

1. Lifestyle Modification (For ALL Women)

2. Hormone Replacement Therapy (HRT) — The Cornerstone

2a. What Is HRT?

2b. Indications

2c. Choosing the Right Regimen

2d. Routes of Administration

Oestrogen Routes

Progestogen Routes